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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Campylobacter jejuni is the leading bacterial cause of foodborne diseases in the 
United States and other developed countries. As a zoonotic pathogen, C. jejuni is well 
adapted in the food production environments, is prevalent in food producing animals, and 
is transmitted to humans via unpasteurized milk, contaminated water, and undercooked 
poultry meat. The extensive use of antibiotics for animal production and human medicine 
has resulted in increasing prevalence of antibiotic resistant Campylobacter. Previously it 
was shown that antimicrobial efflux transporters, such as CmeABC, play key roles in 
both the intrinsic and acquired resistance to structurally diverse antimicrobials. However, 
the roles of antimicrobial efflux systems in facilitating Campylobacter adaptation to 
various environments and the associated molecular mechanisms remain to be determined. 
In this project, we determined the role of salicylate-induced overexpression of cmeABC 
in promoting the emergence of fluoroquinlone-resistant mutants in C. jejuni and 
identified two new efflux transporters that are involved in Campylobacter resistance to 
arsenic compounds. The entire project contains three sets of experiments. In the first set 
of experiments, the induction of the CmeABC multidrug efflux pump by salicylate, 
which is commonly present in medicine and food, was consistently shown by 
transcriptional fusion assays, real time quantitative reverse transcription-PCR (RT-PCR), 
and immunoblotting. The induction not only decreased the susceptibility of 
Campylobacter to ciprofloxacin, but also resulted in an approximately 70-fold increase in 
the observed frequency of emergence of fluoroquinolone-resistant mutants under 
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selection with ciprofloxacin. These findings suggest that exposure of C. jejuni to 
salicylate could conceivably influence the development of antibiotic resistance in this 
pathogenic organism. In the second set of experiments, we determined the role of ArsB, a 
putative membrane efflux transporter, in the resistance of C. jejuni to arsenic compounds, 
which exist in nature and are used as feed additives in poultry production. Inactivation of 
arsB in C. jejuni 11168 resulted in 8- and 4-fold reduction in the MICs of arsenite and 
arsenate, respectively, and complementation of the arsB mutant restored the MIC of 
arsenite to the wild-type level. Additionally, overexpression of arsB in C. jejuni 11168 
resulted in a 16-fold increase in the MIC of arsenite. These results indicate that ArsB is a 
key player in mediating the resistance to inorganic arsenic in Campylobacter.  In the third 
set of experiments, we discovered a novel membrane transporter (named ArsP) that 
contributes to Campylobacter resistance to roxarsone, organic arsenic used as an additive 
in poultry feed. ArsP is predicted to be a membrane permease containing eight 
transmembrane helices, a structural feature distinct from other known arsenic transporters. 
Analysis of multiple C. jejuni isolates from various animal species revealed that presence 
of arsP is associated with elevated resistance to roxarsone. In addition, inactivation of 
arsP in C. jejuni resulted in a 4-fold reduction in the MIC of roxarsone compared to the 
wild-type strain. Furthermore, cloning of arsP into a C. jejuni strain lacking a functional 
arsP led to 8-fold increase in the MIC of roxarsone. Neither mutation nor overexpression 
of arsP affected the MICs of inorganic arsenic including arsenite and arsenate in 
Campylobacter. Moreover, acquisition of arsP gene in NCTC 11168 accumulated less 
roxarsone than the wild type strain lacking arsP gene. These results indicate that ArsP 
functions as an efflux transporter specific for extrusion of roxarsone and contributes to 
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the resistance to organic arsenic in C. jejuni. All together, findings in this project reveal 
important roles of antimicrobial efflux transporters in facilitating Campylobacter 
adaptation to various environments and provide new insights into the pathobiology of C. 
jejuni as a major foodborne pathogen.  
Dissertation Organization 
This dissertation is organized into six chapters, including a general introduction, a 
literature review, three chapters on research for publication, and a final summary. 
Chapter 1 is a general introduction for the Ph.D. project. Chapter 2 is a literature review 
of multidrug efflux transporters in Campylobacter. Chapter 3 has been published in 
Applied and Environmental Microbiology. Chapter 4 and 5 are prepared to be submitted 
to ASM journals. Chapter 6 is the summary of this project which includes the general 
conclusions and future directions. The references of this dissertation are formatted in the 
ASM journal style and are located at the end of chapter 2, 3, 4, and 5. All the tables, 
figures, and legends in chapter 3, 4, and 5 are placed as close as possible to the original 
text references.  
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CHAPTER 2. LITERATURE REVIEW OF MULTIDRUG EFFLUX 
TRANSPORTERS IN CAMPYLOBACTER  
Introduction 
Campylobacter spp. are Gram-negative organisms that grow best at microaerobic 
conditions. Morphologically, Campylobacter cells are spirally curved rods 0.2 to 0.8 µm 
wide and 0.5 to 5 µm long. Campylobacter is recognized as a leading bacterial cause of 
food-borne diseases in the United States and other developed countries (73) and 
Campylobacter infections account for 400 to 500 million cases of diarrhea each year 
worldwide (67). A recent CDC report indicated that campylobacteriosis is estimated to 
affect over 0.84 million people every year in the United States (69). At present, there are 
18 validly named Campylobacter species, including C. canadensis, C. coli, C. concisus, 
C. curvus, C. fetus, C. gracilis, C. helveticus, C. hominis, C. hyointestinalis, C. 
insulaenigrae, C. jejuni, C. lanienae, C. lari, C. mucosalis, C. rectus, C. showae, C. 
sputorum, and C. upsaliensis. According to the published data, C. jejuni and C. coli are 
the most common species associated with Campylobacter enteritis in human (20). 
Typical symptoms of campylobacteriosis include diarrhea (bloody), fever, headache, 
myalgia, nausea, vomiting, and abdominal pain. Usually, campylobacteriosis is self-
limited, and hospitalization and antibiotic treatments are only required in severe cases. In 
addition, C. jejuni is the predominant preceding infection for Guillain-Barré syndrome 
(GBS), which is the most common form of acute neuromuscular paralysis (32). 
C. jejuni and C. coli are increasingly resistant to antimicrobials, which has 
become a significant threat to public health (10-11, 14, 25, 35, 47-48, 60, 70, 74, 78). To 
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counteract the selection pressure from antimicrobials, Campylobacter has evolved 
multiple mechanisms (77), which include (i) synthesis of enzymes to modify/inactivate 
antibiotics (e.g. β-lactamase); (ii) alternation of antibiotic targets (e.g. mutations in gyrA 
or 23S rRNA genes); (iii) protection of antibiotic targets (e.g. synthesis of protective 
protein TetO); (iv) reduced permeability of cellular membranes to antibiotics; and (v) 
active extrusion of antimicrobials out of Campylobacter cells through efflux  transporters 
(e.g. CmeABC). Campylobacter harbors multiple antibiotic efflux transporters and 
several of them have been characterized. In this chapter, we will focus on the new 
information concerning the function and regulation of these efflux transporters. 
CmeABC 
CmeABC is the predominant antibiotic efflux system in C. jejuni and belongs to 
the resistance-nodulation-cell division (RND) superfamily of multidrug efflux 
transporters. This efflux system is encoded by a three-gene operon including cmeA, cmeB, 
and cmeC (41). CmeA is a membrane fusion protein, and its amino acid sequence shows 
similarity to the membrane fusion component in other bacterial efflux systems, including 
MtrC of Neisseria gonorrhoeae, MexA and MexC of Pseudomonas aeruginosa, and 
AcrA of Escherichia coli. CmeB is an inner membrane transporter and exhibits sequence 
homology to AcrB, AcrD, and AcrF of E. coli, MexB and MexF of P. aeruginosa, and 
AcrB of Salmonella typhi. CmeC is an outer membrane protein and is similar to the 
OprM and OprN of P. aeruginosa and TolC of E. coli (41). 
Insertional mutation of cmeB in Campylobacter resulted in increased 
susceptibility to structurally diverse antimicrobial compounds, including ciprofloxacin, 
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norfloxacin, nalidixic acid, cefotaxime, ampicillin, erythromycin, rifampin, tetracycline, 
ethidium bromide, heavy metals(CoCl2 and CuCl2), acridine orange, SDS, tetracycline, 
and bile salts (chenodeoxycholic acid, deoxycholic acid, cholic acid, and taurocholic acid) 
(41, 58). Similar results were also observed with inactivation of cmeC (42), suggesting 
that every component of the CmeABC system is required for conferring antibiotic 
resistance. CmeABC functions synergistically with other mechanisms in conferring high-
level resistance to antibiotics. For example, mutation of cmeB resulted in a 8-fold 
decrease in the minimum inhibitory concentration (MIC) of tetracycline in the 
Campylobacter strains carrying tetracycline resistance gene tet(O) (41, 57); inactivation 
of cmeABC in fluoroquinolone-resistant mutants (carrying specific GyrA mutations) 
rendered the resistant mutants susceptible to ciprofloxacin and enrofloxacin (49); and the 
MICs of erythromycin decreased 8- to 1024-fold upon inactivation of the cmeB gene in 
the macrolide-resistant strains that carried the A2075G, A2074G, or A2074C mutation in 
the 23S rRNA genes (6-7, 19, 43) or modifications in the L4 and L22 ribosomal proteins 
(5). These examples illustrate the important role of CmeABC in the acquired resistance to 
clinically important antibiotics such as macrolide and fluoroquinolone. Recent studies 
also revealed that CmeABC efflux pump contributes to both intrinsic and acquired 
resistance to bacteriocins, antimicrobial peptides produced by bacteria (28-29). 
CmeABC efflux pump contributes not only to multidrug resistance but also to the 
adaptation of Campylobacter in the intestinal tract of animal hosts. As an enteric 
organism, Campylobacter must have the ability to deal with bile compounds, which are 
normally present in the digestive system. Bile contains a group of detergent-like bile salts, 
which exhibit potent bactericidal activity (22). In vitro susceptibility tests indicate that 
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inactivation of cmeABC resulted in dramatically decreased resistance in Campylobacter 
to various bile salts, including cholic acid, chenodeoxycholic acid, taurocholic acid, 
deoxycholic acid, dehydrocholic acid, glycocholic acid, taurodeoxyxholic acid, and 
choleate (41-42). Additionally, Lin et al. demonstrated that CmeABC plays a critical role 
in intestinal colonization of C. jejuni (39, 42). In the chicken model, the cmeABC mutants 
failed to colonize any of the inoculated chickens, while  complementation of the cmeABC 
mutants in trans fully restored the colonization to the level of the wild-type strain (42). 
These findings strongly suggest that facilitating adaptation in the intestinal tract is a 
natural function of CmeABC. 
cmeABC is conserved among different Campylobacter species and is widely 
distributed in Campylobacter isolates (23). This efflux system has been functionally 
characterized in C. jejuni (41-42, 58), C. coli (6, 18), C. lari, C. fetus, and C. 
hyointestinals (23), and contributed to antibiotic resistance in all examined species.  In 
general, the sequences of cmeABC are highly conserved within a species, but significant 
sequence polymorphisms are observed in the cmeABC genes among different 
Campylobacter species (3, 16, 23, 54). In addition, analysis of published 8 whole 
genomes of C. jejuni indicated that all of them contain the CmeABC efflux systems. The 
result of Basic Local Alignment Search Tool (BLAST) against the gene database 
indicated that this efflux system is spread widely in C. jejuni and C. coli as well as other 
Campylobacter species, such as C. upsaliensis, C. fetus, C. lari, C. venerealis, C. gracilis, 
C. showae, and C. rectus. Together, these observations indicate that CmeABC efflux 
pump system is conserved at both the genomic and functional levels in different 
Campylobacter Spp. 
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The expression of cmeABC is modulated by a transcriptional regulator named 
CmeR (37). The cmeR gene (cj0368c) is located immediately upstream of the cmeABC 
operon and encodes a 210-amino acid (aa) protein. The N-terminal sequence of CmeR 
shows homology with the members of the TetR family of transcriptional repressors, 
including QacR of S. aureus, AcrR of E. coli, and MtrR of N. gonorrhoeae (37). Several 
studies demonstrated the increased expression of CmeABC in CmeR mutant strains (24, 
37). CmeR functions as a repressor for cmeABC. Immunoblotting and transcriptional 
fusion demonstrated a significant upregulation of cmeABC in the cmeR mutant 
background compared to the wild-type strain (37). Furthermore, microarray and real-time 
PCR data confirmed the results from immunoblotting and transcriptional fusion assays 
(24). Electrophoretic mobility shift assays (EMSA) demonstrated that purified 
recombinant CmeR binds specifically to an intergenic region (IT) between cmeR and 
cmeABC (37). Specifically, the 16 bp inverted repeat (IR) sequence, 
5’TGTAATAAATATTACA3’, located between cmeR and cmeABC operon, is the 
operator site for CmeR binding and the IR is located between the predicted -10 and -35 
sequences (37). Mutations in the IR or nearby the IR affect the binding of CmeR to the 
promoter of cmeABC, resulting in overexpression of this efflux system (4, 37). 
The cmeABC operon is inducible by bile salts and salicylate (39, 72). 
Transcriptional fusion assays indicated that presence of various bile salts in culture media 
induced the expression of cmeABC by 6- to 16-fold over the basal level of cmeABC 
transcription (39). Moreover, a recent study revealed that salicylate functions as an 
inducer for cmeABC as well. Presence of salicylate in Mueller-Hinton (MH) culture 
resulted in increased expression of cmeABC as demonstrated by immunoblotting, 
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transcriptional fusion assay, and real-time PCR (72). The presence of bile salts or 
salicylate did not alter the expression level of CmeR, suggesting that the induction was 
via altering the function of CmeR. Indeed, EMSA assay and surface plasmon resonance 
showed that the presence of bile salts or salicylate reduced the binding of CmeR to the 
DNA of cmeABC promoter (39, 72). Recently, Lei et al. further confirmed the capacity of 
CmeR to recognize bile acids using isothermal titration calorimetry and fluorescence 
polarization. These findings indicate that certain substrates of CmeABC interact with 
CmeR and induce the expression of the CmeABC efflux system. 
CmeABC not only contributes to antibiotic resistance, but also affects the 
frequency of emergence of fluoroquinolone (FQ) resistant Campylobacter mutants (72, 
76).  Inactivation of cmeB reduced the frequency of emergence, while overexpression of 
cmeABC increased the frequency of emergence of FQ-resistant mutants under antibiotic 
selection (72, 76). This is due to the fact that CmeABC functions synergistically with 
GyrA mutations in conferring fluoroquinolone resistance. Without the function of 
CmeABC, GyrA mutations alone are unable to confer the level of resistance that is 
required for the mutants to survive the selection pressure (46, 76). 
CmeR 
In addition to regulating cmeABC, CmeR functions as a pleiotropic regulator and 
modulates the expression of multiple genes in Campylobacter (24). Microarray data 
revealed that inactivation of cmeR affected the transcription of at least 28 genes in C. 
jejuni. Particularly, CmeR also represses the expression of Cj0035c (a transporter of the 
major facilitator superfamily) and Cj0561c (encoding a periplasmic fusion protein). Two 
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CmeR binding sites (IRs) are identified in the promoter region of cj0561c and CmeR 
directly controls the expression of Cj0561c (24). Both CmeR and Cj0561c are required 
for optimal colonization in vivo as inactivation of either gene reduced the fitness of C. 
jejuni in the intestinal tract of chickens. 
Recently, the crystal structure of CmeR has been determined by Gu et al. (21). 
Similar to other members of the TetR family, CmeR forms a dimeric structure with an 
entirely helical architecture. Each subunit of CmeR is composed of ten α helices and 
could be divided into two domains: an N-terminal DNA binding domain and a C-terminal 
multiligand-binding domain. Distinct from the other members of the TetR family, 
including TetR, QacR, CprB, and EthR, the crystal structure of CmeR revealed that the 
α3 helix, involved in DNA recognition, was replaced by a random coil. To facilitate the 
comparison with the structures of other TetR members, helices of CmeR are numbered 
from the N terminus as α1 (7-29), α2 (36-43), α4 (57-81), α5 (88-104), α6 (106-118), α7 
(a(125-136) and b(138-148)), α8 (152-170), α9 (172-180), and α10 (187-203), in which 
helix α3 has been omitted. Therefore, the N-terminal DNA-binding domain contains 
helices α1, α2, and a random loop (residues 47-53), and the C-terminal ligand-binding 
domain includes helices from α4 to α10 (21, 66). 
The overall structure of the N-terminal DNA-binding domain of CmeR is similar 
to those of the TetR family members. However, CmeR displays some distinct features 
compared with the rest of the TetR family members (21). The first helix of CmeR 
consists of 23 amino acid residues which is relatively long among all structurally known 
members of TetR family. For instance, the lengths of helices α1 in QacR, TetR, and EthR 
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are 16, 13, and 17 residues, respectively. As mentioned above, the lack of α3 helix in 
CmeR is the most striking feature compared with other TetR family members. So far, 
CmeR is the only regulator missing helix α3 among the TetR family. The helix α3 
together with α2 in TetR regulators was considered to form a helix-turn-helix (HTH) 
DNA-binding motif which plays an important role in recognizing target DNA (62). As a 
regulator, CmeR might transform the flexible coil into a helix when bound to the target 
DNA. Further, CmeR functions as a pleiotropic regulator of a large set of genes and the 
flexibility of the DNA-binding domain might permit CmeR to recognize multiple DNA 
sites (66). 
The C-terminal domain of CmeR consists of helices α4 through α10 and five of 
them (α4, α5, α7, α8, and α10) form an anti-parallel five-helix bundle. The crystal 
structure of CmeR indicated that helices α6, α8, α9, and α10 are involved in the 
formation of the dimer (21, 66). The overall structure of the C-terminal domain of CmeR 
is close to that of QacR. The distinct feature of CmeR in C-terminal domain is that the 
helix α9, between the two anti-parallel helices α8 and α10, deviates from the direction of 
α8 by 40°. Therefore, the bending of helix α9 toward the next subunit of the dimer 
ensures the secure interaction between the dimer (21). One unique feature, not found in 
other regulators of TetR family, is the large tunnel-like cavity in each subunit of CmeR. 
This tunnel, surrounded by mostly hydrophobic residues of helices α4–α9 in the C-
terminal domain of CmeR, opens horizontally from the front to the back of each protomer.  
Helices α7 and α8 from one subunit, and α9′ from the other subunit of the regulator make 
the entrance of the tunnel, while helices α4–α6 form the end of this hydrophobic tunnel 
(66). 
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This tunnel is approximately 20 Å in length and occupies a volume of about 1000 
Å, which is distinctly larger than the binding pockets of many other members of the TetR 
family (21). Unexpectedly, a fortuitous glycerol molecule was found to bind in the 
binding tunnel of each monomer. Residues F99, F103, F137, S138, Y139, V163, C166, 
T167, and K170 are responsible for forming this glycerol-binding site. The volume of the 
ligand-binding tunnel of CmeR is large enough to accommodate a few of the ligand 
molecules. The crystal structures of CmeR in complexes with taurocholate and cholate 
were also elucidated, which indicated that these two ligands bind distinctly in the binding 
tunnel. Residues I68, C69, H72, F103, A108, F111, I115, W129, Q134, F137, V163, 
K170, H174, H175’, L176’, and L179’ are involved in taurocholate binding, whereas 
residues L65, C69, F103, A108, F111, G112, I115, W129, F137, Y139, C166, K170, 
P172’, H174, H175’, and L179’ interact with cholate in the tunnel. These quite distinct 
binding manners highlighted the plasticity and promiscuity of the ligand-binding tunnel 
of CmeR (36). 
CmeDEF 
CmeDEF is another RND-type efflux pump identified in C. jejuni.  CmeD 
(Cj1031) is an outer membrane protein of 424 aa, which shares low, but significant 
sequence homology to HefA of H. pylori and TolC of E. coli, the outer membrane 
components of antibiotic efflux systems (38). CmeE (Cj1032) is a membrane fusion 
protein composed of 246 aa, which shares significant homology with the membrane 
fusion protein of HefB in H. pylori. CmeF, similar to CmeB, is an inner membrane 
transporter and is predicted to contain 12-transmembrane (TM) helical domain structure. 
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The sequence of CmeF (1,005 aa) shares homology with many other RND-type efflux 
transporters, such as HefC of H. pylori, and AcrB, AcrD, and AcrF of E.coli (38, 59). The 
low sequence identity between CmeDEF and CmeABC suggests these two efflux systems 
may have different functions and abilities to extrude antibiotics and other toxic 
compounds. 
Several studies determined the contribution of cmeDEF to antimicrobial 
resistance. Pumbwe et al. reported that insertional mutation of cmeF in Campylobacter 
resulted in increased susceptibility to structurally unrelated antimicrobial compounds, 
including ampicillin, ethidium bromide, acridine orange, SDS, sodium deoxycholate, bile, 
detrimide, and triclosan (59). Akiba et al. also reported that the cmeF mutant of 11168 
showed a 2-fold decrease in the resistance to ampicillin and ethidium bromide, but did 
not observe any changes in the susceptibility to the other tested antimicrobials including 
the bile salts (1). Another study by Ge et al. found that inactivation of cmeF in 81-176 
had no effect on the susceptibility to ciprofloxaxin, erythromycin, tetracycline, and 
chloramphenicol. Interestingly, inactivation of cmeF in some Campylobacter strains (81-
176, 21190, and 164) resulted in a 2-4 fold increase in the resistance to multiple 
antimicrobials and toxic compounds, including ciprofloxacin, cefotaxime, rifampicin, 
tetracycline, novobiocin, fusidic acid, ethidium bromide, acriflavine, SDS, triton X-100, 
tween 20, empigen, and different bile salts (1).  In order to examine if the expression of 
CmeABC pump potentially masked the function of CmeDEF on antimicrobial resistance, 
cmeB/cmeF double mutants in 81-176 and 22290 were generated. Compared with the 81-
176 cmeB mutant, the 81-176 cmeB/cmeF double mutant showed a 2-fold decrease in the 
resistance to ciprofloxacin, tetracycline, fusidic acid, acriflavine, and a 2-16 fold decrease 
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in the resistance to various detergents and bile salts. Likewise, in comparison with the 
21190 cmeB mutant, the 21190 cmeB/cmeF double mutant showed a 2-fold increase in 
the susceptibility to fusidic acid, acriflavine, polymyxin B, novobiocin, and a 2-128 fold 
increase in the susceptibility to detergents and bile salts (1). Together, these results 
suggest that the CmeDEF plays a modest role in antibiotic resistance in a strain-
dependent manner and its function is normally masked by that of CmeABC. 
One interesting finding is that either CmeABC or CmeDEF is required for 
maintaining cell viability in certain Campylobacter strains (1). A single mutation of 
either cmeB or cmeF did not affect the viability or growth characteristics of 
Campylobacter (1, 42). However, the cmeB/cmeF double mutation in C. jejuni 81-176 
showed decreased viability in the stationary phase (1). Additionally, repeated 
experiments failed to generate the cmeB/cmeF double mutation in NCTC 11168, 
suggesting that the double mutation is lethal to NCTC 11168 (1, 59).  These results 
suggest that CmeDEF has an important physiological function, which remains to be 
determined in future studies. 
The baseline expression of cmeDEF in Campylobacter is much lower than that  of 
cmeABC as determined by transcriptional fusion and immunoblotting assays (1). The 
regulatory mechanism for cmeDEF is not known and the conditions that may induce the 
expression of cmeDEF have not been determined. CmeR, the transcriptional repressor for 
cmeABC, does not modulate the expression of cmeDEF. 
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CmeG 
CmeG (Cj1375) is one of the predicted MFS (major facilitator superfamily) 
transporters and is present in all the C. jejuni strains sequenced to date. Analysis of amino 
acid sequence revealed that CmeG shows homology to Bmr of B. subtilis and NorA of S. 
aureus (33). Both Bmr and NorA were demonstrated to contribute to multidrug resistance 
in bacteria (33). In addition, CmeG is predicated to be an inner membrane protein and 
possesses 12 transmembrane domains (TMs). Inactivation of cmeG significantly reduced 
the resistance to various classes of antimicrobials including ciprofloxacin, erythromycin, 
tetracycline, gentamicin, ethidium bromide, and cholic acid, while overexpression of 
cmeG enhanced the resistance to various fluoroquinolone antimicrobials, including 
ciprofloxacin, enrofloxacin, norfloxacin, and moxifloxacin, but not to the other 
antibiotics tested in the study (33). Accumulation assays showed that the cmeG mutant 
accumulated more ethidium bromide and ciprofloxacin than the wild-type strain (33). 
These results indicate that CmeG is a functional efflux transporter in Campylobacter. 
An important function of CmeG is its contribution to oxidative stress resistance in 
Campylobacter. Mutation of cmeG increased the susceptibility of C. jejuni to hydrogen 
peroxide and complementation restored the resistance to the wild-type level (33). This 
finding clearly indicates the significant role of CmeG in oxidative stress response, but 
how CmeG is involved in this process is unknown. Additionally, CmeG appears to be 
important for bacterial viability as inactivation of cmeG in C. jejuni 11168 resulted in a 
significant growth defect in conventional culture media and the growth defect was 
completely restored by in trans complementation (33). Furthermore, a cmeG mutant 
16 
 
could not be generated from C. jejuni 81-176 and 81116 (18, 33), suggesting that cmeG is 
an essential gene in certain Campylobacter strains. The expression of cmeG appears to be 
regulated by Fur protein and iron concentrations as inactivation of Fur or depleting iron 
resulted in up-regulated expression of cmeG (30, 55-56). The detailed mechanism for 
cmeG regulation remains to be determined. 
Acr3 
Recently, an arsenic detoxification system has been identified in C. jejuni (75). 
Arsenic compounds are commonly used in poultry industry for promoting growth and 
control of diseases. Thus, the ability to resist the action of arsenic compounds is 
necessary for Campylobacter adaptation in the poultry production environment. Indeed, 
Campylobacter isolates from conventional poultry products had significantly higher 
arsenic resistance than those isolates from antimicrobial-free poultry products (68). The 
arsenic resistance and arsenic-sensing system identified in C. jejuni is encoded by a four-
gene operon and includes a putative membrane permease (ArsP), a transcriptional 
repressor (ArsR), an arsenate reductase (ArsC), and an arsenite efflux protein (Acr3) (75). 
There are two families of arsenite transporters: the ArsB family and the Acr3 family (65). 
The ArsB family has been found only in bacteria and archaea, while the Acr3 family 
exists in prokaryotes and fungi, as well as in plant genomes (17, 31, 64-65). 
Acr3 in C. jejuni consists of 347 amino acids and contains 10 predicted 
transmembrane helices. Presence of the acr3-containing operon is significantly associated 
with elevated resistance to arsenite and arsenate in Campylobacter. Furthermore, 
inactivation of acr3 led to 8- and 4-fold reductions in the MICs of arsenite and arsenate, 
17 
 
respectively, but mutation of acr3 did not affect the susceptibility to the different classes 
of antibiotics tested, including erythromycin, tilmicosin, ciprofloxacin, enrofloxacin, 
oxytetracycline, ceftiofur, and polymyxin B (75). 
The expression of acr3 is directly regulated by ArsR, which is a transcriptional 
regulator encoded by the second gene of the ars operon (75). ArsR is a small regulatory 
protein containing a helix-turn-helix (HTH) DNA-binding motif. In-frame deletion of 
arsR greatly increased the expression of the other three genes in the operon including 
acr3, indicating that ArsR functions as a repressor. Analysis of the ars promoter region 
indicated that there is an 18-bp inverted repeat forming a dyad structure, suggesting a 
binding site for ArsR. Indeed, EMSA showed the direct binding of ArsR to the promoter 
of the ars operon, specifically to the region containing the inverted repeat (75). The 
expression of the ars operon is inducible by arsenite and arsenate and there is a conserved 
metal binding motif (ELCVCDL) in the ArsR protein. Therefore, it is possible that 
arsenic compounds induce the expression of the ars operon by inhibiting the interaction 
of ArsR with the promoter. Indeed, EMSA demonstrated that arsenite, but not arsenate, 
inhibited the binding of ArsR to the promoter DNA, providing an explanation for 
arsenite-induced expression of the operon. Additionally, arsenate is reduced by ArsC to 
arsenite in bacterial cells and thus is also able to induce the expression of the ars operon 
in Campylobacter (75). 
In addition to the Acr3 efflux pump, C. jejuni strains also contain putative ArsB 
and ArsP transporters, which are associated with arsenic resistance. Our recent studies 
showed that mutation of the arsB gene resulted in 8- and 4-fold reduction in the MICs of 
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arsenite and arsenate, respectively, compared to the wild-type strain, while inactivation of 
arsP led to a 4-fold reduction in the MIC of roxarsone (an organic arsenic compound) 
compared to the wild-type strains (71). Additionally, overexpression of arsB and cloning 
of arsP to an arsP-negative strain resulted in 8 fold increase in the MICs of arsenite and 
roxarsone, respectively (71). These findings indicate that Campylobacter harbors 
multiple arsenic efflux transporters that confer resistance to both organic and inorganic 
arsenic compounds. 
Targeting efflux mechanisms to control Campylobacter 
As discussed above, the antibiotic efflux transporters are not only key players in 
the resistance to antibiotics and toxic compounds, but also have important physiological 
functions in Campylobacter, providing promising targets for the control of antibiotic 
resistant Campylobacter. This is especially true with CmeABC, which is essential for 
Campylobacter adaptation in the intestinal tract (41-42). Thus, inhibition of CmeABC 
will not only reduce antibiotic resistance, but also potentially prevent in vivo colonization. 
Inhibition of antibiotic efflux in bacterial cells can be achieved by two different 
approaches. The first one is to inhibit the function of multidrug efflux transporters by 
using efflux pump inhibitors (EPIs) (40, 45, 61). Recently, a promising EPI, Phe-Arg β-
naphthyl-amide dihydrochloride (MC-207,110; PAβN), was found to target the inner 
membrane drug transporter of RND-type efflux pumps and potentiate the activity of 
antimicrobial agents in Pseudomonas aeruginosa (45). So far, PAβN has been 
demonstrated to be effective in potentiating antibiotics against a variety of Gram-negative 
bacteria (2, 8-9, 12-13, 27, 44, 50, 52, 63). Several studies have tried to inhibit CmeABC 
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and efflux in Campylobacter by using PAβN (15, 51-52, 61). The general findings are 
that PAβN has a significant impact on Ery MICs (8 to >64-fold reduction) and that this 
effect is largely due to the inhibition of CmeABC and is especially prominent in EryR 
mutants that don't harbor known target mutations in the 23S RNA genes (61). This EPI 
also showed good potentiating activities for other antimicrobials including rifampin, 
novobiocin, fusic acid, and bile salts. In contrast to findings in other bacteria, multiple 
studies have found that PAβN has limited or no effect on the MICs of FQ antimicrobials 
in Campylobacter (26, 61). Thus PAβN appears to be an effective potentiating agent for 
macrolide antibiotics, but not effective for potentiating FQ antimicrobials in 
Campylobacter. 
The second approach for targeting antibiotic efflux systems is to inhibit their 
production. Recently, Jeon and Zhang reported the feasibility of using antisense peptide 
nucleic acid (PNA) to inhibit the production of CmeABC in Campylobacter (34). PNA 
agents are DNA-mimic synthetic polymers, carrying a pseudo-peptide backbone with 
nucleic acid bases (53). PNA is neutrally charged due to the lack of a phosphodiester 
backbone, giving high affinity to nucleic acids. In addition, the extreme resistance of 
PNA to proteases and nucleases, and its stability in acidic pH have made PNA an ideal 
candidate for various antisense applications (53). An anti-cmeA PNA was used to 
specifically inhibit the expression of CmeABC in C. jejuni (34).  The specific inhibition 
was confirmed by immunoblotting using anti-CmeABC antibodies (34). Importantly, the 
anti-cmeA PNA potentiated the anti-Campylobacter activity of erythromycin and 
ciprofloxacin and resulted in 2- to > 64-fold reduction in their MICs  (34). These results 
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clearly indicated that the feasibility of the PNA antisense technology in controlling 
antibiotic-resistant Campylobacter. 
Conclusions and future directions 
The importance of multidrug efflux pumps in antibiotic resistance and 
pathobiology is increasingly recognized in Campylobacter. It is well documented that the 
antibiotic efflux systems have functions beyond extrusion of antibiotics, and evidence is 
accumulating that they are intertwined with physiological pathways in Campylobacter. 
Thus, it is likely that these efflux systems have uncharacterized functions. Future studies 
should focus on understanding how the antibiotic efflux systems interact with various 
physiological pathways and how they facilitate the adaptation of Campylobacter to 
various niches. Additionally, targeting efflux systems has become a promising approach 
for controlling antimicrobial resistance and preventing Campylobacter colonization in the 
intestinal tract of animal hosts. PAβN has been shown to be effective in potentiating 
macrolide antibiotics such as erythromycin, while anti-cmeA PNA sensitizes 
Campylobacter to both macrolides and fluoroquinolones. To enhance the usefulness of 
the approach, additional EPIs (both synthetic compounds and natural products) should be 
evaluated to inhibit antibiotic efflux systems in Campylobacter. Combination of EPIs 
with PNAs should be also explored to increase the potentiating effects on various 
antibiotics. Additionally, enhanced efforts should be directed toward elucidating the 
crystal structures and structure-function relationship of antibiotic efflux transporters, 
which will eventually facilitate the design of small molecules to block the function of 
efflux pumps. 
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Abstract 
Salicylate, a non-steroidal anti-inflammatory compound, has been shown to 
increase the resistance of Campylobacter to antimicrobials. However, the molecular 
mechanism underlying salicylate-induced resistance has not yet been established. In this 
study, we determined how salicylate increases antibiotic resistance and evaluated its 
impact on the development of fluoroquinolone-resistant Campylobacter mutants. 
Transcriptional fusion assays, real time quantitative reverse transcription-PCR (RT-PCR), 
and immunoblotting assays consistently demonstrated the induction of the CmeABC 
multidrug efflux pump by salicylate. Electrophoretic mobility shift assay further showed 
that salicylate inhibits the binding of CmeR (a transcriptional repressor of the TetR 
family) to the promoter DNA of cmeABC, suggesting that salicylate inhibits the function 
of CmeR. The presence of salicylate in the culture media not only decreased the 
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susceptibility of Campylobacter to ciprofloxacin but also resulted in an approximately 
70-fold increase in the observed frequency of emergence of fluoroquinolone-resistant 
mutants under selection with ciprofloxacin. Together, these results indicate that in 
Campylobacter, salicylate inhibits the binding of CmeR to the promoter DNA and 
induces expression of cmeABC, resulting in decreased susceptibility to antibiotics and in 
increased emergence of fluoroquinolone-resistant mutants under selection pressure.  
Introduction 
Sodium salicylates are commonly used as nonsteroidal anti-inflammatory drugs 
(NSAIDs). The acetyl form of salicylate, aspirin, is used widely in medicines and 
cosmetics. It has been estimated that around 40,000 metric tons of aspirin are consumed 
each year in the world (32). The main function of aspirin is to relieve minor aches and 
pains and reduce fever. Aspirin also has functions in decreasing the incidence of strokes 
and heart attacks (3). Salicylic acid and salicylate are the principal metabolites of aspirin 
(11). Sodium salicylate is also as an antipyretic, antiphlogistic, and analgesic agent in 
livestock and poultry (12). In addition, salicylic acid is a common compound in plants 
and in numerous foods and beverages (13, 33). Therefore, salicylate is available to 
humans and food-producing animals via multiple sources.  
In addition to its effects in mammalian cells, salicylate also alters the 
susceptibility of bacteria to antibiotics. Growth of several bacterial species in the 
presence of salicylate induces nonheritable resistance to multiple antibiotics (25). In 
Escherichia coli, the presence of salicylate increases resistance to multiple antibiotics, 
including quinolones, cephalosporins, ampicillin, nalidixic acid, tetracycline, and 
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chloramphenicol (25, 27). Salicylate-induced multiple antibiotic resistance in E. coli is 
mediated by increased transcription of the marRAB operon. Salicylate inhibits the binding 
of the repressor protein MarR to marO, the operator region of the mar operon, which then 
leads to overexpression of the transcriptional activator protein MarA (4). MarA 
modulates the transcription of a number of genes, including decreased expression of 
OmpF (a porin) and increased expression of multidrug efflux pump AcrAB-TolC, which 
results in a multiple antibiotic resistance (2). Increased resistance to chloramphenicol and 
enoxacin in Salmonella enterica serovar Typhimurium is also due to induction of mar 
regulon by salicylate (31). In Klebsiella pneumoniae, salicylate-induced antibiotic 
resistance is due to increased expression of a MarA homologue, RamA, and the reduced 
production of two porins (5, 7). 
Campylobacter is recognized as a leading bacterial cause of food-borne diseases 
in the United States and other developed countries (30). According to a CDC report, 
campylobacteriosis is estimated to affect over 0.84 million people every year in the 
United States (29). Worldwide, Campylobacter infections account for 400-500 million 
cases of diarrhea each year (28). Antibiotic treatment is recommended when the infection 
by Campylobacter is severe or occurs in immunocompromised patients. However, 
Campylobacter has become increasingly resistant to antimicrobials (18, 24). Among the 
known antibiotic resistance mechanisms in Campylobacter, the CmeABC efflux pump is 
an important player and confers resistance to structurally diverse antibiotics and toxic 
compounds (17). It has been demonstrated that CmeABC belongs to the RND family of 
efflux transporters and is regulated by a transcriptional repressor, CmeR, which binds to a 
specific site in the promoter region of cmeABC (15, 17). Expression of CmeABC is 
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inducible by bile compounds, which interact with the ligand-binding domain of CmeR 
and prevent binding of CmeR to the cmeABC promoter in Campylobacter jejuni (14, 16). 
Furthermore, it has been shown that overexpression of CmeABC in Campylobacter 
significantly increases the frequency of emergence of fluoroquinolone-resistant mutants 
(35). 
Previously, it was shown that growth of Campylobacter in the presence of 
salicylate resulted in a small but statistically significant increase in the resistance to 
ciprofloxacin, tetracycline, and erythromycin (26). Later, Hannula and Hanninen 
confirmed a salicylate-induced increase in resistance to ciprofloxacin in almost all 
examined Campylobacter strains (10). These studies indicated that salicylate modulates 
Campylobacter resistance to antibiotics, but how salicylate influences antibiotic 
resistance and if it affects the emergence of antibiotic resistant Campylobacter mutants 
are unknown. Based on previous findings on salicylate and cmeABC regulation, we 
hypothesized that salicylate modulates antibiotic resistance in Campylobacter by altering 
the expression of the CmeABC efflux pump. To examine this hypothesis, we sought to 
compare the expression levels of cmeABC with or without salicylate, to determine the 
interaction of salicylate with the CmeR regulator, and to assess the impact of salicylate 
on the emergence of fluoroquinolone-resistant Campylobacter mutants.  
Materials and Methods 
Bacterial strains and growth conditions. Bacterial strains and plasmids used in 
this study are listed in Table 1. C. jejuni strains were cultured on Mueller-Hinton (MH) 
agar or in MH broth at 42 °C microaerobically (5% O2, 10% CO2, and 85% N2) in a gas 
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incubator. C. jejuni strains with antimicrobial resistance markers were grown on 
kanamycin (30 µg/ml) or chloramphenicol (4 µg/ml) when appropriate. All strains are 
preserved as 30% glycerol stock at -80 °C.  
Table 1. Bacterial plasmids and strains used in this study 
Bacterial strain or 
plasmid 
Description or relevant genotype Source or 
reference 
Plasmids   
pMW10 Shuttle plasmid with promoterless lacZ  (34) 
pABC11 
 
pMW10 with the cmeABC promoter sequence 
cloned in front of lacZ  
(1) 
pMW561 pMW10 with the promoter of cj0561c inserted 
upstream of lacZ 
(9) 
C. jejuni strains           
NCTC 11168 Wild-type C. jejuni (22) 
11168/pABC11 NCTC 11168 containing pABC11 (1) 
W7/pMW561 11168W7 containing pMW561 (9) 
Antimicrobial susceptibility tests. The MICs of antibiotics against C. jejuni 
NCTC 11168 were determined using either Campylobacter MIC Plates (TREK 
Diagnostic Systems) or a broth microdilution method as described previously (17). All 
assays were repeated at least three times. 
Bacterial growth assays. Overnight culture of C. jejuni NCTC 11168 was diluted 
100 times in fresh MH broth. Cultures were grown in 200-µl volumes in 96-well plate 
and then supplemented with ciprofloxacin (0.125 µg/ml), erythromycin (0.125 µg/ml), 
novobiocin (16 µg/ml), or tetracycline (0.031 µg/ml) alone or together with salicylate 
(100 µg/ml). The plate was incubated at 42°C for 20 h in a microaerobic atmosphere, and 
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optical density at 600 nm was measured by use of FLUOstar Omega instrument (BMG 
Labtech, Offenburg, Germany). 
β-galactosidase assay. To determine if salicylate induced the promoter activity of 
cmeABC, C. jejuni 11168 containing pABC11 (Table 1) was grown in MH broth or MH 
broth supplemented with salicylate (100 µg/ml) for 20 h, and the cells were harvested to 
measure β-galactosidase activity as described in a previous study (1). Since cj0561c is 
also regulated by CmeR (9), we further analyzed the promoter activity of cj0561c in the 
presence of salicylate. The promoter fusion construct for cj0561c was described by Guo 
et al. (9) and is listed in Table 1. All β-galactosidase assays were repeated three times. 
Real-time qRT-PCR. To further assess if cmeABC operon is subject to induction 
by salicylate, C. jejuni NCTC 11168 was cultured in MH broth, with or without salicylate, 
for 20 h. The final concentrations of salicylate in the cultures were 0, 100, and 200 µg/ml. 
Total RNA was extracted from each of the cultures by use of a RNeasy mini kit (Qiagen, 
Valencia, CA) according to the protocol supplied with the product and was further treated 
with a Turbo DNA-free kit (Ambion, Austin, TX) to eliminate DNA contamination. 
Real-time quantitative reverse transcription-PCR (qRT-PCR) analyses were conducted 
using an iScript one-step RT-PCR kit with SYBR green (Bio-Rad) along with a MyiQ 
iCycler real-time PCR detection system (Bio-Rad, Hercules, CA) as described previously 
(16). The primer sets used to detect the transcription level of cmeB (9) and cmeR (16) 
were described in previous publications. The 16S rRNA gene was used for the 
normalization. The qRT-PCR experiment was repeated three times using RNA samples 
prepared from three independent experiments. 
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SDS-PAGE and immunoblotting assay. In order to determine if salicylate alters 
cmeABC expression at the protein level, C. jejuni 11168 was grown overnight in MH 
broth containing 0, 100, and 200 µg/ml of salicylate. Bacterial cells were harvested from 
the cultures, and whole cell proteins were analyzed by SDS–PAGE and western blotting, 
using anti-CmeA, anti-CmeB, anti-CmeC, anti-Cj0561c, and anti-Momp antibodies as 
described previously (9, 17). 
EMSA. To examine if salicylate inhibits CmeR binding to the promoter DNA of 
cmeABC, an electrophoretic mobility shift assay (EMSA) was performed using the 
EMSA Kit (Invitrogen, Carlsbad, CA). Briefly, primers GSF and GSR1 (15) were used to 
amplify the 170-bp promoter region of cmeABC. The purified PCR products in 30-ng 
aliquots with 120 ng of purified recombinant protein (rCmeR) carrying the C69S and 
C166S changes (15, 21) in 10 µl of binding buffer containing 250 mM KCl, 0.1 mM 
dithiothreitol, 0.1 mM EDTA, and 10 mM Tris. The reaction mixtures were 
supplemented with salicylate (10 and 100 µg), taurocholate (10 and 100 µg), or 
ampicillin (10 and 100 µg) and then incubated for 20 min at room temperature. The 
reactions mixtures were then subjected to electrophoresis on a nondenaturing 6% (wt/vol) 
polyacrylamide gel in 0.5 × TBE (44 mM Tris, 44 mM boric acid, 1 mM EDTA [pH 8.0]) 
at 200 V for 45 min. The gel was stained in 1× TBE containing 1× SYBR Gold nucleic 
acid staining solution for 20 min. After washing the gel in 150 ml of distilled H2O for 10 
s, the DNA bands were visualized under UV light at 254 nm.  
Detection of spontaneous fluoroquinolone-resistant mutants. The emergence 
of spontaneous fluoroquinolone-resistant Campylobacter mutants in the presence or 
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absence of salicylate was detected as described previously (35). Briefly, strain NCTC 
11168 was grown on MH agar plates for 20 h under microaerobic conditions. The cells 
were collected and suspended in 1 ml MH broth. The total CFU in the concentrated 
culture were determined by serial dilutions and plating on MH plates. Equal amounts of 
bacterial concentrate were plated onto salicylate-free and salicylate-containing MH plates 
that contained three different concentrations of ciprofloxacin. The concentrations of 
ciprofloxacin used for enumerating the mutants were 0.625, 1.25 and 4 µg/ml, which 
were 5-, 10-, and 16-fold higher, respectively, than the MIC for wild-type NCTC 11168. 
The frequency of emergence of fluoroquinolone-resistant mutants was calculated as the 
ratio of the CFU on ciprofloxacin-containing MH agar plates to the CFU of the 
inoculated culture concentrate. This experiment was repeated three times. The 
significance of differences in the frequencies of emergence of fluoroquinolone-resistant 
mutants between salicylate-treated cultures and nontreated cultures was determined by 
Student’s t test. 
Results 
Salicylate increases Campylobacter resistance to several antibiotics. To verify 
if salicylate affects antimicrobial susceptibility of Campylobacter, we measured the MICs 
of different antibiotics in the absence and presence of salicylate (100 µg/ml). Growth of 
C. jejuni NCTC 11168 with salicylate resulted in a moderate (2-fold) but reproducible 
increase in the MIC of ciprofloxacin in multiple experiments. This result is consistent 
with previous findings reported by others (10, 26). In this study, salicylate did not affect 
the MICs of other examined antimicrobials including azithromycin, gentamicin, 
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florfenicol, nalidixic acid, clindamycin, rifampin, cefotaxime, and streptomycin. 
However, presence of salicylate increased the growth rate of 11168 in the presence of 
various antibiotics, including ciprofloxacin, erythromycin, novobiocin, and tetracycline at 
their corresponding MIC (Fig. 1). Together, these results confirmed that salicylate 
decreased the susceptibility of Campylobacter to antibiotics. It should be pointed out that 
the enhanced resistance induced by salicylate was not inheritable. After removing 
salicylate from the medium, the MIC of ciprofloxacin for strain 11168 returned to the 
baseline level (data not shown). 
 
Figure 1. Effects of salicylate (100 µg/ml) on the growth of C. jejuni 11168 in the 
presence of various antibiotics, including ciprofloxacin (0.125 µg/ml), erythromycin 
(0.125 µg/ml), novobiocin (16 µg/ml), and tetracycline (0.031 µg/ml). The bars represent 
the means and standard deviations of triplicate samples from a single representative 
experiment. 
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Salicylate induces the expression of cmeABC in Campylobacter. To determine 
if salicylate induces the expression of cmeABC, we measured β-galactosidase activity of 
strain 11168/pABC11 grown in the presence or absence of salicylate. Compared to the 
basal level of transcription in MH broth, addition of salicylate (100 µg/ml) to the culture 
resulted in a 3-fold increase in the expression of cmeABC (Fig. 2A). We further examined 
the levels of the cmeB transcript in Campylobacter cultures grown with different 
concentrations of salicylate (0, 100, and 200 µg/ml), using real-time qRT-PCR. As shown 
in Fig. 2B, salicylate induced the transcription of cmeB 2- to 3-folds, in a dose-dependent 
manner. An immunoblotting assay using anti-CmeABC antibodies further confirmed the 
induction of CmeABC by salicylate (Fig. 3). According to densitometric analysis (data 
not shown), the amounts of CmeABC proteins increased 1.5 to 3 fold in the presence of 
salicylate compared to the baseline control (in MH broth). The major outer membrane 
protein (MOMP) band, which was used as an internal control, did not show any changes 
among the samples (Fig. 3). The protein data and the transcriptional results all indicated 
that salicylate is an inducer for CmeABC. 
Since expression of CmeABC is controlled by CmeR (15), we further determined 
if salicylate affected the transcription of cmeR using qRT-PCR. Results from three 
independent experiments did not reveal any significant changes in the transcription level 
of cmeR in the presence of salicylate (data not shown), indicating that salicylate did not 
alter the expression of cmeR. Thus, the enhanced expression of cmeABC by salicylate is 
unlikely to be due to a change in cmeR transcription. 
 
 Figure 2. Induction of the 
Transcriptional fusion (β-
cmeABC in the presence of salicylate (100 µg/ml). The bars represent the means 
standard deviations of triplicate samples from a single representative experiment. (B) 
qRT-PCR results showing the increased transcript level of 
200 µg/ml). Bacterial cells grown in MH broth alone were used as the control for 
baseline expression. The bars represent the mean 
independent experiments. 
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Figure 3. Immunoblotting analysis of CmeA, CmeB, CmeC, Cj0561c, and 
MOMP production in NCTC 11168 grown in 0 (lanes 1, 4, and 7), 100 (lanes 2, 5, and 8) 
or 200 (lanes 3, 6, and 9) µg/ml of salicylate. Whole-cell proteins were used for 
immunoblotting with specific antibodies against the indicated proteins. The position of 
each protein is indicated by an arrow. MOMP is used as an internal control. 
 
Salicylate interferes with CmeR binding to the cmeABC promoter. Since 
salicylate induced expression of CmeABC, but did not alter the transcription of cmeR, we 
hypothesized that salicylate might affect the function of CmeR by reducing its affinity to 
the promoter DNA. To test this hypothesis, we determined the effect of salicylate on the 
binding of CmeR to cmeABC promoter by using EMSA. The results showed that 
salicylate produced a dose-dependent inhibition of CmeR binding to the cmeABC 
promoter DNA (Fig. 4).  Taurocholate is a known inducer of cmeABC and was used as a 
control for inhibition of CmeR binding. Although the inhibition by salicylate was not as 
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strong as that by taurocholate, the inhibitory effect of salicylate on CmeR binding was 
clearly evident (Fig. 4). In contrast, ampicillin, which is not an inducer of cmeABC, did 
not inhibit the binding of CmeR to the cmeABC promoter DNA (Fig. 4).  
 
 
Figure 4. Effects of salicylate, taurocholate, and ampicillin on the formation of 
CmeR-DNA complexes as determined by EMSA. Each reaction mixture contains 30 ng 
cmeABC promoter DNA and 120 ng rCmeR (except lane 1). The amounts of chemicals 
used in the assay are indicated at the top. 
 
Salicylate induces the expression of Cj0561c. In addition to the control of 
cmeABC expression, CmeR also functions as a repressor for Cj0561c (a putative 
periplasmic protein) in Campylobacter by specifically binding to the cj0561c promoter 
(9). Since salicylate inhibited the function of CmeR, we suspected that it might also 
induce the expression of Cj0561c in Campylobacter. To examine this possibility, we 
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evaluated the promoter activity of cj0561c by using a transcriptional fusion construct 
(pMW561) (Table 1). The β-galactosidase activity of strain W7/pMW561 grown in MH 
broth supplemented with 100 µg/ml of salicylate increased 2.5-fold compared with that 
for growth in MH broth without salicylate (Fig. 5). An immunoblotting assay using anti-
Cj0561c antibodies further confirmed the induction of Cj0561c by salicylate (Fig. 3).  
This induction result for Cj0561c is consistent with the result that salicylate interferes 
with the function of CmeR in Campylobacter.  
 
 
Figure 5. Induction of cj0561c in C. jejuni 11168 by salicylate (100 µg/ml), as 
determined by transcriptional fusion (β-galactosidase assay). The bars represent the 
means and standard deviations of triplicate samples from a single representative 
experiment. 
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Salicylate increases the frequency of emergence of fluoroquinolone-resistant 
Campylobacter mutants. Since salicylate induced the expression of CmeABC, we 
further examined if the presence of salicylate modulates the emergence of 
fluoroquinolone-resistant Campylobacter. The results are shown in Table 2. When 0.625 
or 1.25 µg/ml ciprofloxacin were used in the selection plates for enumeration of mutants, 
C. jejuni 11168 exhibited similar frequencies of emergence of fluoroquinolone-resistant 
mutants, regardless of presence of salicylate in the growth medium (~10-6; P ≥ 0.05). 
However, at a ciprofloxacin concentration of 4 µg/ml, incubation of strain 11168 with 
salicylate resulted in a 70-fold increase in the frequency of emergence of ciprofloxacin-
resistant mutants and the difference was statistically different (P < 0.05). These findings 
indicate that salicylate increases the frequency of emergence of fluoroquinolone-resistant 
mutants on plates with a high concentration of ciprofloxacin.  
Table 2. Frequencies of emergence of fluoroquinolone-resistant C. jejuni mutants under 
different selection pressures 
Ciprofloxacin levels 
(µg/ml) 
Frequency of mutant emergencea 
No salicylate Salicylate (100 µg/ml) 
0.625 3.33±1.58×10-6 4.60±2.70×10-6 
1.25 3.77±0.74×10-6 4.16±2.96×10-6 
4 4.24±1.42×10-8 3.23±1.55×10-6* 
a
 Data are mean ± standard deviations of three independent experiments. *, the difference from the 
no-salicylate control is statistically significant (p < 0.05).   
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Discussion 
Results from this study revealed that salicylate-mediated decreases in the 
susceptibility of Campylobacter to antibiotics are due at least partially to induction of 
expression of the CmeABC efflux pump. This conclusion is based on multiple pieces of 
experimental evidence derived from transcriptional fusion assay (Fig. 2A), real time 
qPCRs (Fig. 2B), and immunoblotting assay (Fig. 3). We further showed that salicylate 
inhibits the binding of CmeR to its target promoters (Fig. 4), leading to enhanced 
expression of CmeABC and Cj0561c in the presence of salicylate (Figs. 2, 3, and 5). 
Together, these results provide a molecular basis for salicylate-induced resistance to 
antibiotics in Campylobacter. 
CmeABC efflux system plays an important role in the resistance to antibiotics and 
toxic compounds in Campylobacter (17), and the expression of this efflux pump is 
modulated by CmeR (15). Previous studies demonstrated that overexpression of 
CmeABC results in a modest increases in the MICs to antibiotics, including ciprofloxacin, 
erythromycin, novobiocin, tetracycline, cefotaxime, and fusidic acid (15-16). In this 
study, we found that salicylate caused a small but reproducible increase in the MIC of 
ciprofloxacin and facilitated the growth of Campylobacter in the presence of inhibitory 
concentrations of antibiotics (Fig. 1). This finding is consistent with the results from 
previous studies using salicylate (10, 26).  
CmeR is a pleiotropic regulator and functions as a transcriptional repressor for 
cmeABC and cj0561c (9, 15). Cj0561c is a periplasmic protein and is tightly controlled 
by CmeR due to the presence of two CmeR binding sites in the promoter sequence of 
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Cj0561c (9). Although the exact function of Cj0561c is unknown, a previous study 
showed it contributes to the in vivo fitness of Campylobacter in chickens (9). In this study, 
we found that salicylate induced the expression of both CmeABC and Cj0561c. This 
induction can be explained by the fact that salicylate inhibited the binding of CmeR to 
promoter DNA, as shown by EMSA (Fig. 4). Compared with that by bile salts, which are 
strong inhibitors of CmeR binding (16), the inhibition by salicylate was relatively weak, 
but was visually apparent (Fig. 4). This finding suggests that salicylate releases the 
repression of CmeR on cmeABC and cj0561, leading to increased expression of the two 
genes.  
Salicylate inhibits the function of CmeR, not the expression level of this 
regulatory protein. This conclusion is based on the fact that qRT-PCR did not detect 
altered transcription of cmeR in the presence of salicylate (data not shown). How 
salicylate modulates the function of CmeR is unclear at present, but it is known that 
CmeR has a DNA-binding motif in the N-terminal region and a flexible ligand-binding 
pocket in the C-terminal region (8). It is possible that salicylate interacts with the ligand-
binding pocket and triggers a conformational change in the DNA-binding domain, 
preventing CmeR binding to promoter DNA. This possibility remains to be examined in 
future studies. Based on results from this study and previously known information on 
CmeR regulation, we present a model that depicts the induction mechanisms of salicylate 
in Campylobacter (Fig.6). The binding of salicylate to CmeR appears to be reversible, 
since removal of salicylate from the culture medium restored cmeABC expression to the 
basal level (data not shown).  
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Figure 6. Diagram depicting the molecular basis of salicylate-mediated induction 
of CmeABC and Cj0561c. (A) Baseline expression of the genes in the absence of 
salicylate. Transcription of cmeABC and cj0561c is at a low level due to inhibition by 
CmeR. (B) Induction of the genes by salicylate. When salicylate is present, it inhibits the 
binding of CmeR and ameliorates the repression on cmeABC and cj0561c, leading to 
overexpression of CmeABC and Cj0561c. 
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Salicylate not only increases antibiotic resistance but also promotes the 
emergence of spontaneous fluoroquinolone-resistant Campylobacter under selection 
pressure. In Campylobacter, fluoroquinolone resistance is mediated by target 
modification (GyrA mutations) and by the efflux function of CmeABC (6, 20, 23). A 
single point mutation in the quinolone resistance-determining region of gyrA DNA is 
sufficient to significantly increase the resistance of Campylobacter to fluoroquinolone 
antimicrobials (6, 18-19, 24). The T86I substitution in GyrA confers high-level resistance 
to fluoroquinolones, while the T86K, A70T, and D90N substitutions are associated with 
moderate resistance to fluoroquinolones (18, 24). It is important to point out that 
CmeABC functions synergistically with GyrA mutations in conferring fluoroquinolone 
resistance and that without CmeABC, GyrA mutants are unable to maintain the resistance 
phenotype (18, 35). Thus, the expression level of CmeABC affects the frequency of 
emergence of fluoroquinolone-resistant mutants in Campylobacter (35). In this study, we 
showed that addition of salicylate in the culture media resulted in a 70-fold increase in 
the frequency of emergence of ciprofloxacin-resistant mutants at a higher concentration 
of the antibiotic (4 µg/ml) (Table 2). This result is consistent with our previous finding 
with a cmeR mutant, in which CmeABC was overexpressed, for which the frequency of 
emergence of fluoroquinolone-resistant mutants increased significantly (35). 
For Campylobacter, it is known that different GyrA mutations confer different 
levels of resistance, and the measured frequencies of emergence of resistant mutants vary 
with the concentration of ciprofloxacin in the plates (35). The presence of salicylate in 
the medium did not alter frequencies of emergence of fluoroquinolone-resistant mutants 
(~10-6) when the concentrations of ciprofloxacin in the selection plates were 5 times 
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(0.625 µg/ml) and 10 times (1.25 µg/ml) higher than the MIC (Table 2). This result can 
be explained by the fact that the base-level expression of CmeABC is sufficient and 
overexpression of this efflux pump is not required for the GyrA mutants to survive at low 
selection pressure (0.625 and 1.25 µg/ml) (35). In contrast, with 4 µg/ml of ciprofloxacin, 
those GyrA mutants with lower MICs would require overexpression of cmeABC to 
survive the selection pressure, resulting in a difference in the numbers of detected 
mutants with and without salicylate. These results indicate that salicylate does not affect 
the spontaneous mutation rate but facilitates the emergence of fluoroquinolone-resistant 
mutants under antibiotic selection by inducing the expression of cmeABC. Similar 
findings were obtained in a previous study in which mutation of cmeR (CmeABC 
overexpressed) led to increased emergence of ciprofloxacin-resistant mutants for 
selection with ciprofloxacin at 4 µg/ml but not at 0.625 and 1.25 µg/ml (35). 
In summary, this study identified the molecular mechanism underlying salicylate-
induced antibiotic resistance in Campylobacter and revealed that salicylate promotes the 
emergence of fluoroquinolone-resistant Campylobacter mutants under selection pressure. 
Although these findings were made under laboratory experiments, they might be 
applicable to the ecological niches occupied by C. jejuni under natural conditions. 
Considering the common presence of salicylate in plant and food as well as its 
widespread use in veterinary and human medicine, it is possible that C. jejuni is exposed 
to salicylate in animal reservoirs and in the human host. Such exposure would 
conceivably influence the development of antibiotic resistance in this pathogenic 
organism. Those treating Campylobacter infections with fluororquinolones should 
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consider this possibility and avoid simultaneous use of salicylate-containing medicine or 
salicylate-rich nutrients.  
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Abstract  
Arsenic, a toxic metalloid, exists in the natural environment and its organic form 
is frequently used as a feed additive for animal production. Campylobacter isolates from 
poultry were highly resistant to arsenic compounds and a 4-gene ars operon (containing 
arsP, arsR, arsC, and acr3) was previously found to be associated with arsenic resistance 
in Campylobacter. However, this 4-gene operon is not present in all Campylobacter 
isolates and other arsenic resistance mechanisms in C. jejuni have not been characterized. 
In this study, we determined the role of ArsB, ArsC2 and ArsR3 in arsenic resistance in C. 
jejuni and found that ArsB, but not the other two genes, contributes to the resistance to 
arsenite and arsenate. ArsB is predicted to be a membrane permease with 11 
transmembrane segments. Inactivation of arsB in C. jejuni 11168 resulted in 8- and 4-
fold reduction in the MICs of arsenite and arsenate, respectively, and complementation of 
the arsB mutant restored the MIC of arsenite to the wild-type level. Additionally, 
overexpression of arsB in C. jejuni 11168 resulted in a 16-fold increase in the MIC of 
arsenite. PCR analysis of C. jejuni isolates from different animals hosts indicated that 
arsB and acr3 are widely distributed in various C. jejuni strains, and Campylobacter 
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requires at least one of the two genes for adaptation to arsenic-containing environments. 
These results identify ArsB as a new membrane efflux transporter contributing to arsenic 
resistance in C. jejuni and provide new insights into the adaptative mechanisms of 
Campylobacter in the food producing environments.  
Introduction 
Arsenic is a wildly distributed toxic metalloid in water, soil, and air from natural 
and anthropogenic sources, and exists in both inorganic and organic forms (3, 11, 24). 
The most prevalent inorganic forms of arsenic include trivalent arsenite [AS(III)] and 
pentavalent arsenate [AS(V)]. The trivalent form is more toxic than the pentavalent form 
(3, 11). AS(III) impairs the functions of many proteins by reacting with their sulfhydryl 
groups, while AS(V) is a molecular analog of phosphate, which inhibits oxidative 
phosphorylation and harms the main energy-generation system (24, 44). In order to 
survive arsenic toxicity, microorganisms have developed different mechanisms for 
arsenic detoxification, including reduction of AS(V) to AS(III) by arsenate reductases 
and methylation or extrusion of AS(III) by efflux transporters (26-27, 39).  
The genes encoding arsenic detoxification systems are found on both plasmids 
and chromosomes. Usually, the ars genes are organized as operons, such as arsRBC, 
arsRABC, and arsRDABC, but some ars genes exist singly (4-6, 10, 20, 34, 36, 39). ArsC 
is a small-molecular mass arsenate reductase, which converts AS(V) to AS(III) in the 
cytoplasm (15, 27). As(III) is extruded by AS(III)-specific transporters, such as ArsB and 
Acr3 (27, 39). The activity of ArsB can be ATP-independent or requires the help of ArsA, 
an ATPase (9, 32). A recent study identified a new arsenic detoxification mechanism 
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mediated by ArsM, an AS(III) S-adenosylmethionine methyltransferase, which 
methylates AS(III) to volatile trimethylarsine (26). In addition, there are other Ars 
proteins involved in arsenic resistance. ArsR, a transcription regulator, modulates the 
expression of arsenic resistance genes (22, 29, 39, 42, 48). ArsD, an arsenic 
metallochaperone, transfers As(III) to ArsA and increases the rate of arsenic extrusion (2, 
19, 26, 45). ArsH, an NADPH-flavin mononucleotide oxidoreductase, also contributes to 
arsenic resistance, and its detoxification mechanism is probably through oxidation of 
arsenite to the less toxic arsenate or reduction of trivalent arsenicals to volatile arsines 
that escape from cells (23, 47).  
Campylobacter is considered a leading bacterial cause of food-borne diseases in 
the United States and other developed countries (35). Campylobacter infections account 
for 400 to 500 million cases of diarrhea each year worldwide (30). According to a recent 
CDC report, campylobacteriosis is estimated to affect over 840,000 people every year in 
the United States (35). As a zoonotic pathogen, Campylobacter is highly prevalent in 
food producing animals, including both livestock and poultry (14), and is frequently 
exposed to antimicrobials used in animal agriculture. Roxarsone (4-hydroxy-3-nitro-
phenylarsonic acid), an organoarsenic compound, is extensively used as a feed additive to 
improve weight gain, feed utilization and pigmentation, and control of coccidiosis in the 
poultry industry (7). It has been estimated that approximately 70% of the U.S. broiler 
production units utilizes roxarsone (7), and the total arsenic concentration in the litter is 
approximately 29 mg/kg (12). Given that poultry is the major reservoir for 
Campylobacter, it must be able to deal with the toxicity of arsenic compounds used for 
poultry production. 
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Recently, Wang et al. identified a 4-gene ars operon, which is associated with 
high-level arsenic resistance in Campylobacter (39). This operon encodes a putative 
membrane permease (ArsP), a transcriptional repressor (ArsR), an arsenate reductase 
(ArsC), and an efflux protein (Acr3). The expression of the whole operon is directly 
regulated by ArsR and is inducible by AS(III) and As(V) (39). However, this ars operon 
is not present in all Campylobacter isolates and how those strains without this ars operon 
adapt to arsenic selection is unknown. According to the genomic annotation of C. jejuni 
NCTC 11168 (http://www.lshtm.ac.uk/pmbu/crf/Cj_updated.art), which lacks the 
previously characterized ars operon (25, 39), three putative ars genes are present on the 
chromosome. These include cj0258 (an arsR homolog), cj0717 (an arsC homolog), and 
cj1187c (an arsB homolog), but their functions remain unknown. In this study, we 
determine the roles of these putative ars genes in arsenic resistance and found that 
cj1187c (arsB) contributes to the resistance to AS(III). In addition, we investigated the 
presence of the arsB and acr3 genes in various Campylobacter isolates. The results 
suggest that Campylobacter requires at least one of the two genes for adaptation to 
arsenic-containing environment. 
Materials and Methods 
Bacterial strains and growth conditions. The key bacterial strains and plasmids 
used in this study are listed in Table 1. Escherchia coli DH5α used for genetic 
manipulation was grown in Luria-Bertani (LB) broth or on Mueller-Hinton (MH) agar. 
When required, kanamycin (30 µg/ml), chloramphenicol (10 µg/ml), or ampicillin (100 
µg/ml) was added to the culture media. C. jejuni strains were cultured on MH agar or in 
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MH broth at 42oC microaerobically (5% O2, 10% CO2, and 85% N2). Kanamycin 
(30µg/ml) or chloramphenicol (4 µg/ml) was supplemented to the media when needed.  
Table 1. Bacterial strains and plasmids used in this study 
Bacterial strain or 
plasmid 
Description or relevant genotype Source or 
reference 
Plasmids   
pUOA18 E. coli-C. jejuni shuttle vector (40) 
pUC19 Cloning vector (46) 
pMW10 Promoterless lacZ plasmid (41) 
pArsB pUC19+arsB This study 
pArsBcat pUC19+arsB::cat This study 
pRRK pRR::aphA3 (21) 
pRRKarsB pRRK+arsB This study 
pC2M1 pUC19+arsC2M1 This study 
pC2M1M2 pUC19+arsC2M1+arsC2M2 This study 
pC2M1M2Kan pUC19+arsC2M1+aphA3+arsC2M2 This study 
pR2M1 pUC19+arsR3M1 This study 
pR2M1M2 pUC19+arsR3M1+arsR3M2 This study 
pR2M1M2Kan pUC19+arsR3M1+aphA3+arsR3M2 This study 
strains   
DH5α Plasmid propagation E.coli strain Invitrogen 
NCTC 11168 Wild-type C. jejuni (25) 
11168∆arsB NCTC 11168 derivative, ∆arsB::Cmr This study 
11168∆arsC2 NCTC 11168 derivative, ∆arsC2:: aphA3 This study 
11168∆arsR3 NCTC 11168 derivative, ∆arsR3:: aphA3 This study 
11168∆arsB∆arsC2 NCTC 11168 derivative, ∆arsB::Cmr, 
∆arsC:: aphA3 
This study 
11168+arsB NCTC 11168 derivative, rrs::arsB This study 
11168∆arsB+arsB 11168∆arsB derivative, rrs::arsB This study 
ATCC 33560 Wild-type C. jejuni ATCC 
33560∆arsB ATCC 33560 derivative, ∆arsB::Cmr This study 
CB5-28 Wild-type C. jejuni (39) 
CB5-28∆arsB CB5-28 derivative, ∆arsB::Cmr This study 
CB5-28∆arsC CB5-28 derivative, ∆arsC:: aphA3 (39) 
CB5-28∆arsB∆arsC CB5-28 derivative, ∆arsB::Cmr ∆arsC:: 
aphA3 
This study 
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Chemical compounds and antibiotics. The chemicals and antibiotics used in this 
study were purchased from Sigma-Aldrich Co. LLC (arsenite, arsenate, chloramphenicol, 
kanamycin, ampicillin, copper sulfate, erythromycin, tetracycline, ethidium bromide, 
azithromycin, ciprofloxacin, florfenicol, and clindamycin), Thermo Fisher Scientific Inc. 
( roxarsone, mercury bichloride, and telithromycin), and Alfa Aesar (antimonite). 
Antimicrobial susceptibility tests. The MICs of various arsenic compounds and 
antibiotics against C. jejuni strains were determined using either the agar dilution 
antimicrobial susceptibility testing method according to the protocol from CLSI (1) or the 
broth microdilution method as described previously (18). Each MIC test was repeated at 
least three times. 
Insertional mutation of arsB. Primers arsB1929F and arsB1929R (Table 2) were 
used to amplify a 1929 bp arsB fragment with the SwaI and XbaI restriction sites in the 
middle region of the fragment. The PCR fragment was cloned into the pUC19 between 
the EcoRI and SalI sites, resulting in the construction of pArsB. Primers arsBCat-F and 
arsBCat-R (Table 2) were used to amplify the chloramphenicol resistance cat gene from 
pUOA18 using the Phusion High-Fidelity DNA Polymerase (NEB). After the XbaI 
digestion, the cat cassette was ligated to the SwaI and XbaI digested pARSB to obtain 
plasmid pArsBcat, which was then transformed into E. coli DH5α. Suicide vector 
pArsBcat was introduced into C. jejuni NCTC 11168 using an electroporator (Gene 
Pulser Xcell System; Bio-Rad Laboratories). Transformants were selected on MH agar 
containing chloramphenicol at 4 µg/ml. The insertion of cat cassette into the arsB gene of 
C. jejuni 11168 was confirmed by PCR analysis.  
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Table 2. PCR primers used in this study 
Primers Sequence (5’→3’) 
arsB1929F ACAAGGAATTCATGGCTATGATTTAGGGC 
arsB1929R ATCATGTCGACCCATAACTTGTCCTTTCG 
arsBCat-F CGGTTCTAGATGGAGCGGACAACGAGTAAA 
arsBCat-R GCTTGGATCAGTGCGACAAACTGGGATT 
comarsB-F GCCGCTAGCAAGGAGATTTAAATGCTTGCTTTTTTTATTTTTTT 
comarsB-R GGTGCTAGCTTAGACAATAAGAGCAAAAAGAGAA 
gidAKanF TATGGTACCCGCTTATCAATATATCTATAGAATG 
gidAKanR AGCTCTAGAGATAATGCTAAGACAATCACTAAA 
arsBgidAF CATCATAAACCTCCAACCATT 
arsBgidAR AAGAACTATCCCAAACCAAG 
arsR3M1-F TGGGAATTCGAGGCTTTAATCAACACTTA 
arsR3M1-R TAAGGTACCTTTCATCGGCATTTTCACAT 
arsR3M2-F CGATCTAGATGTGAAAATGCCGATGAAAA 
arsR3M2-R ATTCTGCAGACCATGCACTAGCAAAGGAA 
arsC2M1-F TGGGAATTCTTACGATTGTTCAGCTCACA 
arsC2M1-R GCTGGTACCAAGCATCCATAGCTTTCTTT 
arsC2M2-F TTGTCTAGACCAAGTTGTATTAAGCGTCCT 
arsC2M2-R AATCTGCAGCCATGATCTGTCATAGCCAC 
16sarsB-F ATCGTAGATCAGCCATGCTA 
16sarsB-R GATAATCAACCCAACCAAAGT 
arsB-F1 AGGATAATCAACCCAACCAAAGT 
arsB-R1 CGTCCATGGAATTTACCTATTTG 
arsB56F GGAATTTACCTATTTGGGTAT 
arsB1185R ATATTAATGCCTTTTCTAGCC 
cje1733F ATGTTAGGTTTTATCGATAGAT 
cje1733R TCATGAGGCTTGATTCATTTTT 
Insertional mutagenesis of arsC2 (cj0717). Primers arsC2M1-F and arsC2M1-R 
were used to amplify the 5’ part of arsC2 and its upstream region (arsC2M1), while 
Primers arsC2M2-F and arsC2M2-R were used to amplify the 3’ part of arsC2 and its 
downstream region (arsC2M2). After EcoRI and KpnI digestion, the arsC2M1 PCR 
product was cloned into the EcoRI and KpnI digested pUC19, resulting in the 
construction of pC2M1. The digested arsC2M2 PCR product was cloned into the XbaI 
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and PstI digested pC2M1, resulting in the construction of pC2M1M2. Primers gidAKanF 
and gidAKanR (Table 2) were used to amplify the aphA3 gene encoding kanamycin 
resistance from pMW10 using the Phusion High-Fidelity DNA Polymerase (NEB). After 
the KpnI and XbaI digestion, the Kanr cassette was ligated to the KpnI and XbaI digested 
pC2M1M2 to obtain plasmid construct pC2M1M2Kan, which was then transformed into 
E. coli DH5α. Suicide vector pC2M1M2Kan was then electroporated into C. jejuni 
NCTC 11168. Transformants were selected on MH agar plates containing 30 µg/ml of 
kanamycin. The insertion of the aphA3 gene into arsC2 in the transformants was 
confirmed by PCR using primers arsC2M1-F and arsC2M2-R.  
Insertional mutagenesis of arsR3 (cj0258). Primers arsR3M1-F and arsR3M1-R 
were used to amplify the 5’ part of arsR3 and its upstream region (arsR3M1), while 
primers arsR3M2-F and arsR3M2-R were used to amplify the 3’ part of arsR3 and its 
downstream region (arsR3M2). After EcoRI and KpnI digestion, the arsR3M1 PCR 
product was cloned into the EcoRI and KpnI digested pUC19, resulting in the 
construction of pR3M1. The digested arsR3M2 PCR product was cloned into the XbaI 
and PstI digested pR3M1, resulting in the construction of pR3M1M2. As mentioned 
above, primers gidAKanF and gidAKanR (Table 2) were used to amplify the aphA3 gene 
encoding kanamycin resistance from pMW10 using the Phusion High-Fidelity DNA 
Polymerase (NEB). After the KpnI and XbaI digestion, the Kanr cassette was ligated to 
the KpnI and XbaI digested pR3M1M2 to obtain plasmid construct pR3M1M2Kan, 
which was then transformed into E. coli DH5α. Suicide vector pR3M1M2Kan was then 
electroporated into C. jejuni NCTC 11168. Transformants were selected on MH agar 
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plates containing 30 µg/ml of kanamycin. The insertion of the aphA3 gene into arsR3 in 
the transformants was confirmed by PCR using primers arsR3M1-F and arsR3M2-R. 
Complementation of the ∆arsB::Cmr mutant. The ∆arsB::Cmr mutant was 
complemented by inserting a wild-type copy of arsB between the 16S and 23S rRNAs as 
described by Muraoka and Zhang (21). Briefly, primers comarsB-F and comarsB-R were 
used to amplify the intact arsB gene including its ribosome binding site. The amplicon 
was digested with XbaI and cloned into the pRRK plasmid, which contains an aphA3 
cassette in the opposite orientation to the ribosomal genes, to obtain plasmid construct 
pRRKarsB. The direction of the insertion was confirmed by primers 16sarsB-F and 
16sarsB-R. The construct with arsB in the same transcriptional direction as the ribosomal 
genes was selected and used as the suicide vector to insert the arsB gene into the 
chromosome of the arsB mutant. The complemented strains were selected on MH agar 
containing 30 µg/ml of kanamycin and were confirmed by PCR. 
Overexpression of arsB in C. jejuni NCTC 11168. The suicide plasmid 
pRRKarsB constructed for complementation was electroporated into wild-type C. jejuni 
NCTC 11168 wild type strain, resulting in the insertion of an extra copy of arsB in the 
chromosome. Transformants were selected on MH agar plates containing 30 µg/ml of 
kanamycin and confirmed by PCR.  
Real-time qRT-PCR. To determine if the arsB gene is inducible by arsenic 
compounds, C. jejuni NCTC 11168 was cultured in MH broth with or without added 
arsenite and arsenate for 20 h. The final concentrations of arsenite and arsenate in the 
culture were 0.125, 0.25, and 0.5 times of their corresponding MIC in NCTC 11168. 
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Total RNA was extracted from three biological replicate cultures using the RNeasy mini 
kit (Qiagen) according to the protocol supplied with the product and further treated with 
the Turbo DNA-free kit (Ambion) to eliminate DNA contamination in each preparation. 
For real-time quantitative reverse transcription-PCR (qRT-PCR), primers arsB-F1 and 
arsB-R1 (Table 2) specific for arsB were designed using the Primer3 online interface 
(http://frodo.wi.mit.edu/). Real-time qRT-PCR analyses were conducted using the iScript 
one-step RT-PCR kit with SYBR green (Bio-Rad) along with the MyiQ iCycler real-time 
PCR detection system (Bio-Rad, Hercules, CA), and the16S rRNA gene was used for 
normalization as described in a previous publication (17).  
Analysis of ars gene distribution by PCR. To determine the distribution of the 
arsB and acr3 genes in various C. jejuni isolates, arsB-specific primers (arsB56F and 
arsB1185R) and acr3-specific primers (cje1733F and cje1733R) (39) were designed from 
the genomic sequence of C. jejuni NCTC 11168 and RM1221, respectively, and used in 
PCR analyses with the genomic templates of different C. jejuni strains and the Ex Taq 
polymerase (TaKaRa Bio Inc., Japan). These C. jejuni isolates were derived from human, 
chicken, and turkey. PCR was performed in a volume of 50 µl containing 0.2 µM of 
primers, 250 µM of deoxynucleoside triphosphates, and 1.25 U of TaKaRa Ex Taq 
polymerase. Annealing temperature at 50oC and elongation time for 1 min 10 sec were 
used for the PCR reactions. 
  
69 
 
Results 
Genetic features of arsB, arsC2, and arsR3. arsB encodes a putative arsenic 
efflux membrane protein (428 amino acids) and shows amino acid sequence homology to 
ArsB in Shewanella sp. ANA-3 (32% identity; E=8e-55) (31), Staphylococcus aureus (33% 
identity; E=2e-65) (16), Escherichia coli (32% identity; E=3e-54) (8, 33, 37), and 
Acidithiobacillus caldus (33% identity; E=1e-57) (38). ArsB contains eleven probable 
transmembrane helices predicted by TMHMM2.0 (Fig. 1). Analysis of several published 
genome sequences of C. jejuni strains showed that the arsB gene is immediately 
downstream of the gidA gene (Fig. 2A), which encodes a putative tRNA uridine 5-
carboxymethylaminomethyl modification enzyme (13). RT-PCR (using primers 
arsBgidAF and arsBgidAR) amplified a transcript spanning both gidA and arsB, 
suggesting that these two genes form an operon and are co-transcripted. cj0717 encodes a 
small protein (109 aa), which is predicted to belong to the arsenate reductase (ArsC) 
family and the Yffb subfamily. Yffb is an uncharacterized bacterial protein encoded by 
the yffb gene, marginally similar to the amino-acid sequences of classical arsenate 
reductases (ArsC) (Fig. 2B). cj0258 encodes an ORF of 81 aa, which is predicted to 
contain a helix-turn-helix motif at aa 35-56 and belongs to the arsR family (13, 25). To 
differentiate cj0258 from the asrR gene and cj0717 from the arsC gene indentified in a 
previous study (39), we named them as arsR3 and arsC2 in this study, respectively (Fig. 
2B and C). 
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Figure 1. The membrane topologies of ArsB predicted by TMHMM. The 
transmembrane domains are shaded in red. The blue line indicates loops facing inside 
(cytoplasma), while the pink line depicts loops facing outside (periplasmic space). The 
numbers at the bottom indicate the amino acid numbers in ArsB. 
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Figure 2. Diagrams showing the genomic localizations and mutant generation of 
various ars genes. (A) Genomic organization of arsB and inactivation of arsB by 
insertion of a choramphenicol resistance cassette. (B) Genomic localization of arsC2 and 
inactivation of this gene by insertion of a kanamycin resistance cassette. (C) arsR3 and its 
flanking gene. Inactivation of arsR3 was accomplished by insertion of a kanamycin 
resistance cassette. (D) Complementation of the arsB mutant by insertion of an extra 
copy of the arsB gene downstream of 16S rRNA. (E) The ars operon identified in C. 
jejuni CB5-28 and inactivation of arsC by insertion of a kanamycin resistance cassette. 
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Role of arsB, arsC2, and arsR3 in arsenic resistance. To define the role of arsB, 
arsC2, and arsR3 in arsenic resistance in Campylobacter, their insertional mutants were 
compared with the wild-type strain NCTC 11168 for susceptibility to arsenic compounds. 
According to the MIC results from the agar dilution method, inactivation of arsB resulted 
in 8- and 4-fold reduction in the MICs of arsenite and arsenate, respectively, while 
mutation of arsC2 or arsR3 did not affect the MICs of arsenite and arsenate (Table 3). 
All three mutants showed no changes in the MIC of roxarsone. Chromosomal 
complementation of arsB restored the MIC of arsenite to wild type, and over-expression 
of arsB showed 16-fold increase in the MIC of arsenite compared to the wild-type strain. 
Interestingly, chromosomal complementation could not restore the MIC of arsenate to the 
wild-type level and over expression of arsB showed no change in the MIC of arsenate 
compared to the wild-type strain. Furthermore, we transferred the arsB mutation to two 
additional Campylobacter strains (ATCC 33560 and CB5-28) by natural transformation. 
Inactivation of arsB in ATCC 33560 resulted in 8-fold reduction in the MICs of arsenite 
and had no affect on the MIC of arsenate and roxarsone (Table 3). Inactivation of arsB in 
CB5-28, which harbors a 4-gene ars operon as described in a previous study (39), did not 
affect the MICs of arsenite, arsenate, and roxarsone, suggesting the function of arsB in 
CB5-28 is masked by the fully functional ars operon. 
  
73 
 
Table 3. The MICs of roxarsone, arsenite and arsenate in various C. jejuni strains as 
determined by the agar dilution method* 
  MIC (µg/ml)  
Strains Arsenite Arsenate Roxarsone 
NCTC 11168 8 512 8 
11168∆arsB 1(↓8) 128(↓4) 8 
11168∆arsC2 8 512 8 
11168∆arsR3 8 512 8 
11168∆arsB∆arsC2 1(↓8) 128(↓4) 8 
11168∆arsB+arsB 128 128 8 
11168+arsB 128(↑16) 512 8 
ATCC 33560 8 32 8 
33560∆arsB 1(↓8) 32 8 
CB5-28 64 1024 64 
CB5-28∆arsB 64 1024 64 
CB5-28∆arsC 8 64 64 
CB5-28∆arsB∆arsC 4(↓2) 64 64 
*
 the numbers in parentheses indicate fold-changes, either increase (↑) or decrease (↓) 
Mutation of the arsB did not affect the susceptibility to the other antibiotics. 
To examine if arsB, arsC2, and arsR3 are associated with resistance to other heavy 
metals and antibiotics, we compared the susceptibilities of the arsB, arsC2, and arsR3 
mutants with the wild-type strain to antimonate, copper sulfate, mercury bichloride, 
erythromycin, tetracycline, ethidium bromide, azithromycin, ciprofloxacin, florfenicol, 
telithromycin, and clindamycin. The results showed no differences between the wild type 
and mutants in the susceptibilities to these compounds (data not shown), indicating that 
these genes do not confer resistance to other heavy metals and antibiotics. 
The arsB is inducible by arsenite and arsenate. To determine if the expression 
of the arsB is inducible by arsenic compounds, strain NCTC11168 was cultured in MH 
broth with different concentrations of arsenite and arsenate. The transcription levels of 
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arsB in these cultures were compared with those grown in MH broth without arsenic 
compounds using real time qRT-PCR. As shown in Figure 3, the expression of arsB was 
induced in a dose-dependent manner. At 0.5 times of MIC, both arsenite and arsenate 
produced approximately 16-fold induction in the expression of arsB. This result clearly 
indicates that the arsB gene in Campylobacter is inducible by both arsenite and arsenate.  
 
 
 
Figure 3. Dose-dependent induction of arsB in 11168 by arsenite and arsenate. 
The concentrations of the arsenic compounds supplemented into the culture media are 
labeled at the bottom of the panel. 
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Distribution of arsB and acr3 genes in Campylobacter isolates. Data described 
above indicated that ArsB contributes to arsenic resistance in C. jejuni. Additionally, 
Acr3 is associated with high-level of arsenic resistance in certain Campylobacter strains 
(39). We determined the distribution of the arsB and acr3 genes in various 
Campylobacter isolates of different animal origins. As shown in Table 4, arsB was 
present in 76 of the 98 isolates examined in this study, while acr3 were present in 58 of 
the 98 isolates. Interestingly, all the tested strain contains at least one of the two genes. 
Furthermore, arsB is more prevalent in chicken (97.1%) and human (92.0%) isolates than 
in turkey isolates (50.0%) (p < 0.0001 and p < 0.005), while the prevalence of acr3 is 
higher in turkey isolates (84.2%) than in chicken (45.7%) (p < 0.005) and human (40.0%) 
(p < 0.005) isolates. 
Table  4. Distribution of arsB and acr3 in C. jejuni isolates of different origins  
Source 
of 
isolates 
Total 
number arsB-positive acr3-positive 
Positive with 
both arsB and 
acr3 
Positive with 
either arsB or 
acr3 
Chicken 35 34 (97.1%) 16 (45.7%) 15 (42.9%) 35 (100.0%) 
Turkey 38 19 (50.0%) 32 (84.2%) 13 (34.2%) 38 (100.0%) 
Human 25 23 (92.0%) 10 (40.0%)   8 (32.0%) 25 (100.0%) 
total 98 76 (77.6%) 58 (59.2%) 36 (36.7%) 98 (100.0%) 
Discussion 
The results from this study identified ArsB as a membrane transporter involved in 
arsenic resistance in C. jejuni. This conclusion is based on the following findings. First, 
inactivation of arsB resulted in reduced resistance to both arsenite and arsenate. Second, 
complementation of the arsB mutant restored the MIC of arsenite (but not arsenate) to 
that of the wild-type strain. Third, overexpression of arsB in C. jejuni 11168 increased 
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the MIC of arsenite by 16-fold, but did not affect the MIC of arsenate. These results 
suggest that ArsB in C. jejuni is a specific efflux transporter for arsenite, but not for 
arsenate. However, arsenate can be converted to arsenite by ArsC in bacteria including C. 
jejuni, where arsenite can be subsequently extruded by ArsB and Acr3 (39). Thus, ArsB 
contributes to the resistance to arsenate in an indirect manner. These results are consistent 
with the arsB findings on in other bacterial species. 
The ArsB in C. jejuni shares homology with the other members of the ArsB 
family. The ArsB transporter is employed by many bacteria as an arsenic detoxification 
method and is proposed to have 12 membrane-spanning regions (43). ArsB appears to be 
an uniporter which extrudes As(III) at a moderate rate using membrane potential. In some 
cases, with the help from ArsA (ATPase), ArsB can extrude As(III) more efficiently (27). 
Several previous studies also showed that Sb(III) is a substrate for certain ArsB 
transpoters (28). In this study, we found that the ArsB in C. jejuni does not play a role in 
the resistance to other heavy metals and antibiotics. The inability of C. jejuni ArsB to 
extrude Sb(III) is different from the result reported in other bacteria (28) and suggests 
that the ArsB in C. jejuni is more or less unique. Indeed, the predicted transmembrane 
topology of the ArsB in C. jejuni contains 11 transmembrane domains, instead of 12 of 
typical ArsB proteins, which might explain the difference in substrate specificities.  
The contributions of arsB to arsenic resistance vary in different Campylobacter 
strains. The role of ArsB in mediating arsenic resistance to As(III) is more prominent in 
those strains that lack the ars operon, such as NCTC 11168 and ATCC 33560 (Table 3). 
On the contrary, inactivation of arsB in the highly resistant CB5-28 strain (containing an 
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ars operon) did not change the MIC of arsenite (Table 3). To test if the function of ArsB 
is masked by the presence of the ars operon, we constructed an arsB and arsC double 
knockout strain (CB5-28∆arsB∆arsC) in the CB5-28∆arsC background (39). Compared 
to CB5-28∆arsC, CB5-28∆arsB∆arsC showed 2-fold reduction in the MIC of arsenite, 
but not 8-fold reduction as observed in NCTC 11168 (Table3). This could be explained 
by the fact that the polar effect caused by the arsC mutation did not totally inactivate the 
function of acr3, as qRT-PCR showed, that the transcript of acr3 was reduced 10-fold in 
the arsC mutant compared with that in the wild-type strain (39). Thus, the reduced 
expression of acr3 still plays a role in arsenite resistance. These results suggest that the 
function of arsB is most likely masked in those C. jejuni strains harboring a fully 
functional ars operon.  
The level of arsenic resistance mediated by ArsB in C. jejuni is not as high as that 
mediated by the ars operon. This could be explained for two reasons. The published data 
in other bacteria indicated that ArsB functions more efficiently when facilitated by ArsA 
(ATPase) (9, 27). However, analysis of the whole genomes of C. jejuni did not identify 
an arsA homology in these strains. Thus, the lack of arsA in C. jejuni might reduce the 
efflux ability of ArsB. In addition, the expression level of arsB might be another factor 
affecting its contribution to arsenic resistance. As show in Table 3, artificial 
overexpression of arsB in C. jejuni NCTC 11168 resulted in a drastic increase in the 
resistance to arsenite, to a level that is even higher than the resistance conferred by the 
ars operon. These findings suggest that ArsB mediated arsenic resistance level in 
Campylobacter is mainly dependent on the expression level of arsB.  
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The putative arsR (arsR3) genes did not contribute to arsenic resistance in C. 
jejuni NCTC 11168. As a transcriptional repressor, ArsR modulates the expression of ars 
genes through interaction with the arsenite substrate (39). In this study, the induction 
experiment revealed that addition of arsenite or arsenate in culture media induced the 
expression of arsB, and the induction was dose-dependent (Fig. 3). Thus, we speculated 
that the expression of arsB is modulated by an ArsR like regulator. However, inactivation 
of arsR3, which is separated from the arsB gene on chromosome, did not affect the 
expression of arsB in C. jejuni NCTC 11168, suggesting that the expression of arsB is 
not modulated by arsR3 and is likely regulated by an unknown mechanism. 
The putative arsC (arsC2) genes did not contribute to arsenic resistance C. jejuni 
NCTC 11168. Conversion of AS(V) to AS(III) by arsenate reductase and then extrusion 
by arsenite transporters is an important detoxification mechanism used by many bacterial 
organisms (15, 39). The previously characterized ars operon in C. jejuni contains an arsC, 
which mediates arsenic resistance in Campylobacter (39). Inactivation of arsC2 in C. 
jejuni NCTC 11168 did not change the susceptibility to arsenic compounds. Additionally, 
we inactivated arsC2 in the arsB mutant background of C. jejuni NCTC 11168, and the 
the arsB and arsC double knockout did not further alter the resistance to arsenate 
compared to the arsB mutant (data not shown), further suggesting that arsC2 is not 
involved in arsenic resistance in Campylobacter.  
Since arsenic compounds are extensively used as feed additives in the poultry 
industry, Campylobacter is frequently exposed to arsenic toxicity. In order to survive the 
selection pressure, Campylobacter has acquired detoxification mechanisms. A previous 
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study identified a four-gene ars operon contributing to arsenic resistance in 
Campylobacter. However, not all the Campylobacter strains harbor this system (39). In 
this study, we identified an additional membrane transporter contributing to arsenic 
resistance in Campylobacter, suggesting that there are at least two arsenic efflux systems 
(Acr3 and ArsB) in Campylobacter. Interestingly, the prevalence of both arsB and acr3 
in human isolates is similar to those in chicken isolates, but differ from those in turkey 
isolates (Table 4). According to a report from American Meat Institute on April 2009, per 
capita consumption of chicken was five times more than that of turkey in 2007. In 
addition, poultry is the main reservoir for human C. jejuni infections. Thus, the big 
portion of Campylobacter infections is probably caused by consumption of chicken. This 
might explain that the presence of ars genes in human isolates is similar to those in 
chicken isolates. Furthermore, the results revealed a broad distribution of arsB and acr3 
genes (ars operon) in C. jejuni isolates of different animal origins (Table 4) and suggest 
that at least one of the two genes is required for the adaptation of Campylobacter in 
arsenic-rich niches. These findings provide new insights into the adaptative mechanisms 
of Campylobacter in the poultry production system. 
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Abstract  
Roxarsone (4-hydroxy-3-nitro-phenylarsonic acid), an organo arsenical, is used as 
a feed additive in the poultry industry for growth promotion. Campylobacter jejuni, a 
major foodborne pathogen causing gastroenteritis in humans, is highly prevalent in 
poultry and is reportedly resistant to arsenic compounds. Although bacterial mechanisms 
involved in the resistance to inorganic arsenic have been well understood, the molecular 
basis for organic arsenic resistance has not been described. In this study, we report the 
identification of a novel membrane transporter (named ArsP) that contributes to organic 
arsenic resistance in Campylobacter. ArsP is predicted to be a membrane permease 
containing eight transmembrane helices, distinct from other known arsenic transporters. 
Analysis of multiple C. jejuni isolates from various animal species revealed that the 
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presence of an intact arsP gene is associated with elevated resistance to roxarsone. In 
addition, inactivation of arsP in C. jejuni resulted in a 4-fold reduction in the MIC of 
roxarsone compared to the wild-type strain. Furthermore, cloning of arsP into a C. jejuni 
strain lacking a functional arsP led to 8-fold increase in the MIC of roxarsone. Neither 
mutation nor overexpression of arsP affected the MICs of inorganic arsenic including 
arsenite and arsenate in Campylobacter. Moreover, acquisition of arsP gene in NCTC 
11168 accumulated less roxarsone than the wild type strain lacking arsP gene. Together, 
these results indicate that ArsP functions as an efflux transporter specific for extrusion of 
roxarsone and contributes to the resistance to organic arsenic in C. jejuni. 
Introduction 
Campylobacter, a Gram-negative microaerobic bacterium, is a leading bacterial 
cause of food-borne diseases and Campylobacter infections account for 400 to 500 
million cases of diarrhea each year in developed and developing countries countries (22). 
A recent estimate from CDC indicated that campylobacteriosis account for 9% of 
foodborne illness (over 840,000 people) every year in the United States (26). C. jejuni 
and Campylobacter coli are the two most important species that cause food-borne 
infections of humans, and raw poultry meat is the main source of these two pathogens 
(11). Roxarsone (4-hydroxy-3-nitro-phenylarsonic acid), an organoarsenic compound, is 
extensively used as a feed additive in poultry industry to control bacterial and coccidial 
infections and improve weight gain, feed utilization and pigmentation (6). It has been 
estimated that roxarsone was utilized in approximately 70% of the U.S. broiler 
production units (6), and the concentrations of roxarsone used in feed formulations vary 
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from 22.7 to 45.4 g/ton (9). Roxarsone is excreted into fresh litter, and then converted to 
inorganic arsenate [As(V)] in composted litter via the bioconversion processes (9, 28). 
The total arsenic concentration in the litter ranges from 15 to 48 mg/kg (9, 12, 28).  
In bacteria, several mechanisms for arsenic detoxification have been characterized, 
including reduction of AS(V) to AS(III) by arsenate reductases and extrdusion or 
methylation of AS(III) (19-20, 30). The arsenic detoxification systems are encoded by 
various ars genes including arsA, arsB, arsC, arsD, arsH, arsM, and arsR. These ars 
genes can be organized as operons, such as arsRBC, arsRABC, and arsRDABC, or exist 
singly on bacterial chromosome (3-5, 8, 15, 25, 29-30). ArsA functions as an ATPase, 
which is an energy source for ArsB (7, 23), while ArsB functions an AS(III)-specific 
transporter (20, 30). As arsenate reductase, ArsC converts As(V) to AS(III) in the 
cytoplasm (13, 20), and then As(III) is extruded by other AS(III)-specific transporters (20, 
30). ArsD is an arsenic metallochaperone which transfers As(III) to ArsA and increases 
the rate of arsenic extrusion (2, 14, 19, 32). ArsH is an NADPH-flavin mononucleotide 
oxidoreductase, and the detoxification mechanism is probably through oxidation of 
arsenite to the less toxic arsenate or reduction of trivalent arsenicals to volatile arsines 
that escape from cells (17, 35). ArsM is an AS(III) S-adenosylmethionine 
methyltransferase, which methylates AS(III) to volatile trimethylarsine (19). ArsR 
functions as a transcription regulator, which controls the expression of other ars genes 
(16, 21, 30-31, 36).  
Campylobacter is well adapted in the poultry production system and must have 
means to overcome the toxic effects of arsenic compounds. Recently, a four-gene ars 
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operon associated with high-level resistance to inorganic arsenic was identified in 
Campylobacter (30). This operon encodes a putative membrane permease (ArsP), a 
transcriptional repressor (ArsR), an arsenate reductase (ArsC), and an efflux protein 
(Acr3). The expression of this operon is directly regulated by ArsR, which binds to the 
ars promoter DNA and controls the expression of the ars genes. Insertional mutation of 
acr3 and arsC revealed that the two genes contribute to arsenite and arsenate resistance, 
but had no effects on the MIC of roxarsone in Campylobacter.(30). However, the 
function of ArsP has not been characterized. In general, the molecular mechanisms 
directly involved in organic arsenic (roxarsone) resistance have not been described in any 
bacteria. In this study, we identify ArsP as a specific mechanism for roxarsone resistance 
in Campylobacter. Analysis of multiple C. jejuni isolates from various animal species 
revealed that presence of an intact arsP gene is associated with elevated resistance to 
roxarsone. In addition, inactivation of arsP in C. jejuni resulted in a 4-fold reduction in 
the MIC of roxarsone compared to the wild-type strain. Furthermore, cloning of arsP into 
a C. jejuni strain lacking a functional arsP led to 8-fold increase in the MIC of roxarsone. 
Moreover, acquisition of arsP gene in NCTC 11168 accumulated less roxarsone than the 
wild type strain lacking arsP gene. Together, these results indicate that ArsP functions as 
an efflux transporter specific for roxarsone and contributes to the resistance to organic 
arsenic in C. jejuni.  
Materials and Methods 
Bacterial strains and growth conditions. The key bacterial strains and plasmids 
used in this study are listed in Table 1. Escherichia coli DH5α used for genetic 
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manipulation was grown in Luria-Bertani (LB) broth or on LB agar supplemented with 
kanamycin (30 µg/ml), chloramphenicol (10 µg/ml), or ampicillin (100 µg/ml). C. jejuni 
strains were cultured on Mueller-Hinton (MH) agar or in MH broth at 42oC 
microaerobically (5% O2, 10% CO2, 85% N2). When needed, kanamycin (30 µg/ml) or 
chloramphenicol (4 µg/ml) was supplemented into the media. 
Table 1. Key plasmids and bacterial strains used in this study 
Bacterial strain or 
plasmid 
Description or relevant genotype Source or 
reference 
Plasmids   
pUC19 Cloning vector (33) 
pDRH265 pUC19 with 1.4 kb cat-rpsL cassette (10) 
pArsPC pUC19+arsP+cat-rpsL This study 
pRY112 Shuttle vector (34) 
pRY112+arsP pRY112+arsP This study 
pRY112+4ars pRY112 containing the 4-gene ars operon This study 
Strains    
DH5α Plasmid propagation E.coli strain Invitrogen 
NCTC 11168 Wild-type C. jejuni (18) 
11168+arsP NCTC 11168 derivative, pRY112+arsP This study 
11168+4ars NCTC 11168 derivative, pRY112+4ars This study 
CB5-28 Wild-type C. jejuni (30) 
CB5-28∆arsC CB5-28 derivative, ∆arsC::Kanr (30) 
CB5-28∆arsP CB5-28 derivative, ∆arsP::cat-rpsL This study 
Chemical compounds and antibiotics. The chemicals and antibiotics used in this 
study were purchased from Sigma-Aldrich Co. LLC (arsenite, arsenate, chloramphenicol, 
kanamycin, streptomycin, and ampicillin) and Thermo Fisher Scientific Inc. (roxarsone). 
Antimicrobial susceptibility tests. The MICs of various arsenic compounds and 
antibiotics against C. jejuni strains were determined using the agar dilution antimicrobial 
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susceptibility testing method according to the protocol from CLSI (1) with modifications. 
Every MIC test was repeated at least three times. C. jejuni ATCC 33560 was used as a 
quality control organism in this study. 
Construction of the arsP mutant. Primers AspT-F and ArsPT-R (Table 2) were 
used to amplify a 1.8 kb arsP fragment with two PsiI sites in the middle region of the 
fragment. The PCR fragment was cloned into the pUC19 in the SmaI sites, resulting in 
the construction of pArsP. The chloramphenicol resistance cat::rpsL cassette was 
prepared by digesting pDRH265 (10) with SmaI and subsequent purification with agarose 
gel extraction (QIAquick gel extraction kit; Qiagen, Valencia, CA). The cassette was then 
ligated into the PsiI site of arsP in pArsP to yield the pArsPC plasmid. Suicide vector 
pArsPC was introduced into C. jejuni CB5-28 using electroporation. Transformants were 
selected on MH agar containing chloramphenicol at 4 µg/ml. The insertion of cat-rpsL 
cassette into the arsP gene was confirmed by PCR analysis.  
Table 2. Key primers used in this study 
Primers Sequence (5’→3’) 
S1730-F GTTCCTGTTCTACCATACCG 
S1730-R TAGCCACGCCTAAAATAATC 
Ars1-F CATTCATTTTAGAGTTATTGCGTATAAAACATACT 
ArsPN-R CCATGTTTAAGAGCTCTTGTAGATCAC 
ArsPT-F CATCCATATACAAACTTCCAATACCCC 
ArsPT-R CCTGCGGAAAATACTTCGATATCTATGCC 
ArsPW-F ACATACTGGTTCTAAATTTCTGATCAAACG 
ArsPW-R AATCCAGAAAGCAAGGACTATCAACCT 
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Cloning of the arsP and the ars operon into C. jejuni NCTC 11168. The entire 
arsP gene including its promoter region was amplified from strain CB5-28 by PCR using 
primers Ars1-F and ArsPN-R (Table 2). The PCR product was cloned into the SmaI-
digested plasmid to construct pRY112+arsP. The constructed plasmid pRY112+arsP 
was sequenced and confirmed that no mutations in the cloned sequence occurred. The 
shuttle plasmid, pRY112+arsP, was transferred into NCTC 11168 by conjugation. The 
strain was named 11168+arsP. The entire ars operon including arsP, arsR, arsC, and 
acr3 was amplified from strain CB5-28 by PCR using primers ArsPW-F and ArsPW-R. 
The PCR product was cloned into the SmaI-digested pRY112 plasmid to construct 
pRY112+4ars. The constructed plasmid pRY112+4ars was sequenced and confirmed 
that no mutations in the cloned sequence occurred. The shuttle plasmid pRY112+4ars 
was transferred into NCTC 11168 by conjugation. The strain was named 11168+4ars.  
PCR and sequence analysis of arsP. To detect the distribution of arsP with in 
various C. jejuni isolates, the S1730-F and S1730R primers (Table 2) were used to 
amplify an intragenic region of the arsP gene. Since the arsP gene in some strains (C. 
jejuni NCTC 11168)  are pseudogenes, if a positive PCR product was obtained, the whole 
coding region of arsP was amplified using another pair of primers, ArsPW-F and 
ArsPW-R, and the product was then sequenced in the DNA facility at Iowa State 
University.  PCR was performed in a volume of 50 µl containing 0.2 µM of primers, 250 
µM of deoxynucleoside triphosphates, and 1.25 U of TaKaRa Ex Taq polymerase. 
Annealing temperature at 51oC and elongation time for 1 min were used for the primer 
pair of S1730-F and S1730R, while annealing temperature at 55oC and elongation time 
for 4 min were used for the primer pair of ArsPW-F and ArsPW-R.  
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Roxarsone accumulation assay. To determine if ArsP contributes to reduce 
intracellular concentration of roxarsone, accumulation assay was conducted using C. 
jejuni NCTC 11168 and 11168+arsP. NCTC 11168 and 11168+arsP were inoculated on 
MH agar plates and incubated microaerobically for 24 h. Bacterial cells were collected 
from the plates, inoculated into fresh MH broth (200 ml), and then incubated at 42oC with 
shaking at 160 rpm. After 4-5 h incubation, the cells were harvested by centrifugation, 
washed once in PBS buffer, and then resuspended in PBS to 1010~11 CFU/ml. Three 
different tubes were prepared for each sample. After incubation at 37oC for 10 min, 
roxarsone was added to a final concentration of 500 µg/ml. Aliquots (1.0 ml) were taken 
after 15 min, and immediately mixed with 5.0 ml of ice-cold PBS. Bacterial cells were 
harvested by centrifugation at 4oC at 6000 g for 5 min, and washed twice with 10 ml of 
ice-cold PBS. The cells were resuspended in 0.5 ml PBS and then disrupted by 
ultrasonication. The supernatant was taken after centrifugation at 15,000 x g for 5 min 
and filtered with a 0.45 µm filter. HPLC analysis was performed on a Beckman Coulter 
126 HPLC, equipped with a photodiode array detector (model 168) and a model 508 
autosampler (Beckman Coulter, Inc., Brea, CA). The mobile phase was monopotassium 
phosphate (0.05 M) : acetic acid (10%) : methanol = 90 : 7 : 3 (V/V/V) at a flow rate of 
1.0 ml/min. A universal reversed phase Supelcosil ABZ+Plus column 
(150 mm × 4.6 mm × 5 µm, Supelco, Bellefonte, PA) was used at room temperature. A 
standard curve was prepared by measuring the peak area from PBS containing serially 
diluted roxarsone and used to determine the concentration of roxarsone in the samples.  
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Results 
Arsenic resistance varies in Campylobacter strains of different animal origins. 
To determine if arsenic resistance in Campylobacter is associated with the origin of 
isolation, we examined the MICs of various arsenic compounds in C. jejuni isolates from 
different animal species. In total, 131 C. jejuni isolates (35 from chicken, 27 from human, 
35 from sheep, and 34 from turkey) were evaluated by the agar dilution method (Tables 3, 
4, and 5). In general, MICs of roxarsone, arsenite, and arsenate ranged from 4 to 256 
µg/ml, 1 to 256 µg/ml, and 16 to >1024 µg/ml, respectively. The MIC50 of roxsarone for 
the isolates from sheep is lower than those for the isolates from chicken, human, and 
turkey (Table 3); the MIC50 of arsenite for the isolates from sheep is equal to those from 
human and turkey, but lower than that from chicken (Table 4); and the MIC50 of arsenate 
for isolates from sheep is lower than those from human, turkey, and chicken (Table 5). A 
similar trend was also observed with the MIC90 of the three tested arsenic compounds. 
Statistical analysis with the Kruskal-Wallis Test (Nonparametric ANOVA) indicated that 
the MICs of C. jejuni from different animal species are significantly different in the 
resistance to roxarsone (p < 0.005), arsenite (p < 0.002), and arsenate (p < 0.0001). 
Further Dunn’s Multiple Comparisons Test indicated that the MICs of roxarsone for the 
sheep isolates are significantly lower than those of the human (p < 0.01), chicken (p < 
0.05), and turkey isolates (p < 0.05); the MICs of arsenite for the sheep isolates were 
significantly lower than those of the chicken isolates (p < 0.001); the MICs of arsenate 
for the sheep isolates are significantly lower than those of the chicken (p < 0.001) and 
turkey isolates (p < 0.001); and the MICs of roxarsone, arsenite, and arsenate for the 
human, chicken, and turkey isolates are not significantly different.  
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Table 3. Roxarsone MIC distributions in C. jejuni isolates of different origins 
Isolates Total number 
Numbers of isolates inhibited by ROX 
(µg/ml) MIC50/MIC90 
(µg/ml) 4 8 16 32 64 128 256 512 
Chicken 35 2 11 7 4 11 0 0 0 16/64 
Human 27 5 4 4 5 5 3 1 0 32/128 
Sheep 35 1 23 6 3 2 0 0 0 8/32 
Turkey 34 0 7 18 7 0 1 1 0 16/32 
Table 4. Arsenite MIC distributions in C. jejuni isolates of different origins 
Isolates Total number 
Numbers of isolates inhibited by AS(III) 
(µg/ml) MIC50/MIC90 
(µg/ml) 1 2 4 8 16 32 64 128 256 
Chicken 35 0 2 1 8 9 7 8 0 0 16/64 
Human 27 2 0 3 9 6 0 5 2 0  8/64 
Sheep 35 0 0 8 23 0 4 0 0 0  8/32 
Turkey 34 0 1 10 9 5 2 6 0 1  8/64 
Table 5. Arsenate MIC distributions in C. jejuni isolates of different origins 
Isolates Total 
number 
Numbers of isolates inhibited by AS(V) 
(µg/ml) MIC50/MIC90 
(µg/ml) 16 32 64 128 256 512 1024 >1024 
Chicken 35 0 5 10 1 9 6 4 0 256/1024 
Human 27 6 6 4 1 4 4 0 2 64/512 
Sheep 35 6 19 2 2 6 0 0 0 32/256 
Turkey 34 1 4 4 13 3 3 3 3 128/1024 
Genetic features of arsP. arsP (cje1730) is the first gene in the 4-gene ars 
operon and encodes a putative transmembrane permease (315 aa) (Fig. 1A). As predicted 
by TMHMM 2.0, ArsP has eight putative transmembrane helices (TMS) and a large 
 hydrophilic loop (67 aa) in the central portion (between the fourth and fifth helices) of t
protein (Fig. 2). The large central hydrophilic loop is predicted to be outside the inner 
membrane, facing the periplasmic space. Thus
different from that of ArsB and Acr3. Additionally, ArsP shares little sequen
with ArsB or Acr3, which are transporters for As(III) extrusion. These observatio
suggest that ArsP may have the 
GeneBank database, there are ArsP homologs in other bacterial 
functions remain unknown. The amino acid lengths of analyzed ArsP homologues from 
~300 to ~350 and all of them contain 8 TMS with hydrophilic loops between the fourth 
and fifth TMSs, ranging from 49 to 100 
likely that ArsP also plays a role in arsenic resistance in 
Figure 1. Diagrams showing the genomic organization of 
ars genes into C. jejuni 11168
of arsP by insertion of a choramphenicol resistance cassette. (
CB5-28 to the shuttle plasmid pRY112, which 
by conjugation. (C) Cloning of the 
pRY112, which was then transferred
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Figure 2. The membrane topologies of ArsP predicted by TMHMM. The 
transmembrane domains are shaded in red. The blue line indicates loops facing inside 
(cytoplasma), while the pink line depicts loops facing outside (periplasmic space). The 
numbers at the bottom indicate the amino acid numbers in ArsP. A large hydrophilic loop 
(67 aa) is in the central portion (between the fourth and fifth helices) of the ArsP.  
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 Figure 3. Sequence alignment of ArsP homologs in various bacterial species using 
ClustalW. The lengths of 
with C. jejuni, the identities are greater than 36% (>3E
conserved at the N- and C
region of the proteins, which corresponds to the large hydrophil
The colors of the residues indicate their physicochemical properties. Red represents small 
(small and hydrophobic (include aromatic except Y)
AVFPMILW. Blue represents acid
represents basic amino acids
sulfhydryl, amine, and G acid amino acids, including STYHCNGQ.
residues in that column are identical in all sequences in the alignment. ":" me
conserved substitutions have been observed.  "." means that semi
are observed. 
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Contribution of arsP to the arsenic resistance in C. jejuni. To determine the 
role of arsP in arsenic resistance in C. jejuni, insertional mutagenesis was used to 
construct an isogenic mutant. The arsP mutant was compared with the parent strain CB5-
28 as well as CB5-28∆arsC for the susceptibility to arsenic compounds using the agar 
dilution method (Fig. 1A). According to MIC results from the agar dilution method, 
inactivation of arsP resulted in a 4-fold reduction in the MICs of roxarsone, arsenite, and 
arsenate, respectively, while inactivation of the downstream arsC gene resulted in 4-fold 
and 32-fold reductions in the MICs of arsenite and arsenate, respectively, but did not 
affect the MIC of roxarsone (Table 6). This finding suggests that arsP is associated with 
roxarsone resistance in Campylobacter. Since the arsP mutation causes a polar effect on 
the expression of the downstream genes in the ars operon, we further analyzed the 
function of arsP by cloning the gene into NCTC 11168, which lacks arsP and does not 
contain a functional ars operon. According to MIC results from the agar dilution method, 
acquisition of the single arsP gene in NCTC 11168 resulted in an 8-fold increase in the 
MICs of roxarsone, but not in the MICs of arsenite or arsenate (Table 6). When the entire 
ars operon was cloned into NCTC 11168, it resulted in 4-fold, 8-fold, and 2-fold increase 
in the MICs of roxarsone, arsenite, and arsenate, respectively. These results indicate that 
arsP specifically contributes to the resistance to roxarsone, but not to arsenite or arsenate. 
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Table 6. The MICs of roxarsone, arsenite, and arsenate in various C. jejuni constructs 
(µg/ml)* 
Strains    Roxarsone  Arsenite  Arsenate  
11168  16  16  1024  
11168+arsP  128(↑8)  16  1024  
11168+4ars  64(↑4)  128(↑8)  2048(↑2)  
CB5-28  32  64  2048  
CB5-28∆arsP  8(↓4)  16(↓4)  512(↓4)  
CB5-28∆arsC 32  16(↓4)  64(↓32)  
*
 the numbers in parentheses indicate fold-changes, either increase (↑) or decrease (↓) 
Correlation of arsP with increased resistance to roxarsone in different C. 
jejuni strains. To examine the association between arsP and the enhanced resistance to 
roxarsone, the presence of arsP in different C. jejuni isolates were determined using PCR.  
In total, 10 C. jejuni strains were used for this purpose. Statistical analysis of the PCR 
and MIC data with Wilcoxon rank sum test with continuity correction indicated that the 
presence of an intact arsP is significantly (p < 0.01) associated with elevated resistance to 
roxarsone (Table 7), further confirming that arsP encodes a roxarsone-resistant 
transporter in various C. jejuni strains. The PCR results also showed that an intact arsP 
gene is not always linked with arsC and acr3 as reported in a previous study (30). For 
example, strains CB4-4, CB1-17, CT3-2, and Clev9100 contain an intact arsP gene; 
however, they do not have the arsC and acr3 genes. On the contrary, strains CB7-22, 
CB3-6, CB7-22 do not contain an arsP gene from PCR amplification, while they have 
both arsC and acr3. Strains RM1221 and CB5-28 are the two strains that contain the 4-
gene ars operon including arsP, arsR, arsC, and acr3 (Table 7). These results further 
confirm that arsP is associated with roxarsone resistance in C. jejuni. 
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Table 7. Presence of arsP detected by PCR and its association with elevated resistance to 
roxarsone 
Strains  MICs (µg/ml)  Presence of intact arsP  
RM1221   128 + 
CB5-28     64  + 
CB4-4   256 + 
CB1-17     64  + 
CT3-2     64  + 
Clev9100   128  + 
NCTC11168     16 -a 
CB7-22     16  -b 
CB3-6     16  -b 
CT3-7     16  -b 
a
 arsP is a pseudogene in NCTC11168 
b  absence of arsP by PCR detection 
“-” indicates frame shift mutations in arsP, or lack of arsP 
The arsP gene is not inducible by roxarsone. To determine if the transcriptional 
level of arsP gene is inducible by roxarsone, CB5-28 strain was cultured in MH broth 
with different concentrations of roxarsone. The transcriptional level of arsP in cultures 
supplemented with or without roxarsone did not differ as measured by qTR-PCR (data 
not shown). This result suggests that arsP is not inducible by roxarsone.  
ArsP reduces intracellular accumulation of roxarsone. An accumulation assay 
using HPLC was performed to assess whether ArsP functions as an efflux transporter for 
roxarsone. The wavelength was 337 nm and the retention time was 5.2 min for roxarson 
(Fig. 4B). The linear regression equation was y = (x – 287.54) / 11176 with R2 of 0.9999, 
where y is the concentration of roxarsone, and x is the peak area of the sample. The 
NCTC 11168 wild type, which does not have a functional arsP gene, accumulated 44.8% 
more roxarsone than 11168+arsP (containing an intact arsP gene) (Fig. 4A). This result 
 suggests that ArsP functions as an efflux transporter, extruding roxarsone out of 
Campylobacter cells. 
 
Figure 4. Intracellular accumulation of roxarsone
in NCTC 11168 WT and 11168
deviation of triplicate samples in one representative experiment (
Chromatogram of the HPLC test to determine roxarsone accumulation in 
This chromatogram shows the absorbance levels of light at 
at 5.2 min represents the detection
 
Discussion 
The results from this study identify ArsP as a novel membrane transporter 
mediating resistance to organic arsenic in 
multiple pieces of evidence. Inactivation of 
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arsP. Each bar represents the mean and standard 
p < 0.02
337 nm over time. 
 of roxarsone.   
C. jejuni. This conclusion is supported by 
arsP resulted in 4-fold reduction in the MIC 
 
). (B) 
Campylobacter. 
The peak 
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of roxarsone, while cloning of a functional arsP into a C. jejuni strain lacking a 
functional arsP showed 8-fold increase in the MIC of roxarsone, but not to arsenite and 
arsenate.  Additionally, ArsP reduced intracellular accumulation of roxarsone in C. jejuni 
and is associated with elevated resistance to roxarsone in various strains. These findings 
indicate that ArsP is a resistance mechanism specific for organic arsenic. Based on the 
results from this study and previously known information regarding arsenic resistance in 
Campylobacter, the various mechanisms involved in arsenical detoxification mechanisms 
are summarized in Figure 5. 
 
 
Figure 5. Diagram illustrating the currently known arsenical detoxification 
mechanisms in Campylobacter. Campylobacter has an arsenic reductase (ArsC), which 
converts arsenate to arsenite, two types of arsenite transporters (ArsB and Acr3), and 
another transporter specifically extruding roxarsone out of the cells.  
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Due to the use of roxarsone in poultry production, Campylobacter spp. in poultry 
must be able to deal with the toxicity and selective pressure from arsenic compounds. A 
previous study indicated that the Campylobacter isolates from conventional poultry 
products had significantly higher roxarsone MICs than those isolated from antimicrobial-
free poultry products, suggesting that the association of the roxarsone use in conventional 
poultry facilities with the development of high-level roxarsone resistance in 
Campylobacter spp. in poultry (24). In this study, we demonstrated that the presence of 
an intact arsP is associated with increased resistance to roxarsone, but not to arsenite and 
arsenate, in various C. jejuni isolates (Table 7). This observation plus the findings from 
the mutagenesis and cloning experiments established ArsP as a key resistance mechanism 
for roxarsone, providing a molecular explanation for the prevalence of roxarsone-
resistant Campylobacter in poultry. Although arsP is found to be in the same operon with 
arsC and acr3 in certain C. jejuni strains, it is functionally distinct from the other two 
genes which confer resistance to arsenite and arsenate (30). Additionally, it is also found 
that arsP does not have to be associated with arsC and acr3 (Table 7) (30) and may 
function independently in mediating roxarsone resistance. These findings suggest that 
arsP is evolved differently from other ars genes.  
In this study, we tested the MICs of arsenic compounds for the C. jejuni isolates 
from chicken, turkey, human, and sheep. An interesting finding is that the MICs of 
roxarsone for sheep isolates were significantly lower than those isolates from human, 
chicken, and turkey. This is probably due to the fact that the sheep industry does not use 
roxarsone as a feed additive, while roxarsone is extensively used on chicken and turkey 
farms. Interestingly, human C. jejuni isolates showed similar roxarsone resistance to 
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those isolates from turkey and chicken. This could be explained by the fact that poultry is 
the main reservoir for human C. jejuni infections. Thus the roxarsone resistance in the 
human isolates might be originated from poultry. These observations suggest that the use 
of roxarsone selects for arsenic-resistant Campylobacter that may be subsequently 
transmitted to humans. 
Although ArsP contributes to roxarsone resistance, its expression is not inducible 
by roxarsone. Previously it is revealed that arsP is regulated by ArsR, which is encoded 
in the same ars operon as arsP, arsC and acr3 (30). The induction of the ars operon is 
through the inhibition of ArsR binding to the promoter DNA, which is mediated by 
conformational change in ArsR triggered by arsenite binding (27). Thus, arsenite is the 
true inducer of ArsR, and the arsenate-mediated induction is via bioconversion of 
arsenate to arsenite by ArsC reductase in Campylobacter. In this study, the presence of 
roxarsone in culture did not induce the expression of arsP. This result indicates that 
roxarsone does not directly induce the ars operon. However, roxarsone can be converted 
to organic arsenic in chicken litter through biological processes (9) and is a potential 
indirect inducer for the ars operon in the poultry production environment. Additionally, 
the MICs of roxarsone for the isolates containing the arsP genes range from 64 to 256 
µg/ml (Table 7). The wide range of MICs suggests the differential expression of arsP and 
the existence of unknown regulatory mechanisms for arsP in those isolates. This 
possibility remains to be determined in future studies. 
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CHAPTER 6. SUMMARY 
In this dissertation, the specific induction of CmeABC by salicylate was 
demonstrated, and the induction was shown to reduce the susceptibility of C. jejuni to 
fluoroquinolone antibiotics and promote the emergence of antibiotic resistant mutants. 
Additionally, our studies identified ArsB and ArsP as new efflux transporters for arsenite 
and roxarsone, respectively, which contribute significantly to arsenic resistance in C. 
jejuni. These findings significantly enhance our knowledge about the functions of 
antimicrobial efflux systems in Campylobacter and indicate that these systems are 
important players in facilitating Campylobacter adaptation to various niches. 
Despite the fact that these findings were made under laboratory conditions, they 
may be extrapolated to the natural environments occupied by Campylobacter. For 
example, salicylate is commonly present in plant and food, and is widely used in 
veterinary and human medicine. Exposure of Campylobacter to salicylate is expected 
during host colonization and transmission through the food chain. Since salicylate 
induces the expression of CmeABC, such exposure may have an unwanted consequence 
in promoting the development of antibiotic resistance. Likewise, arsenic compounds are 
present in nature and are used as feed additives for poultry production. As Campylobacter 
is highly prevalent in poultry, arsenic usage would select for arsenic-resistant 
Campylobacter and influence the ecology and evolution of Campylobacter in animal 
reservoirs. At this stage, acquisition of arsenic resistance is not found to influence the 
susceptibility of Campylobacter to clinically important antibiotics, but it is unknown if 
arsenic resistance mechanisms confer cross resistance to biocides and disinfectants. This 
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possibility awaits further investigation in future studies. Additionally, future attention 
should be given to understanding the interaction between the antimicrobial efflux systems 
and other physiological pathways as such efforts will likely discover novel physiological 
functions of these efflux transporters. Ultimately, the knowledge gained on antimicrobial 
efflux systems will potentially facilitate the development of rationalized strategies to 
control Campylobacter and its antibiotic resistance in clinical settings or in animal 
reservoirs. 
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